{"3LIrYNwAAAAJ": [["Nhu-An Pham", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Arvind Singh Mer", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Nikolina Radulovich", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Geoffrey Liu", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Benjamin Haibe-Kains", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Quan Li", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Michael Cabanero", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Ruoshi Shi", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Christine Ng", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Hirotsugu Notsuda", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Ming Li", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Joshua C Rosen", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Yu-Hui Wang", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Laura Tamblyn", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Ni Liu", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Ming-Sound Tsao", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Vibha Raghavan", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Nadeem Moghal", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Sebastiao N Martins-Filho", 2020, "Organoid Cultures as Preclinical Models of Non\u2013Small Cell Lung Cancer"], ["Nina Chang", 2020, "Malignant mesothelioma in situ: morphologic features and clinical outcome"], ["Francoise Galateau-Salle", 2020, "Malignant mesothelioma in situ: morphologic features and clinical outcome"], ["H Jan", 2020, "Malignant mesothelioma in situ: morphologic features and clinical outcome"], ["Sanja Dacic", 2020, "Malignant mesothelioma in situ: morphologic features and clinical outcome"], ["Anja C Roden", 2020, "Malignant mesothelioma in situ: morphologic features and clinical outcome"], ["Richard Attanoos", 2020, "Malignant mesothelioma in situ: morphologic features and clinical outcome"], ["Andrew Churg", 2020, "Malignant mesothelioma in situ: morphologic features and clinical outcome"], ["Marc De Perrot", 2020, "Malignant mesothelioma in situ: morphologic features and clinical outcome"], ["Shun Lu", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Jeremy J Erasmus", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Noriko Motoi", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Giuseppe Pelosi", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Paul Bunn", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Jin-Mo Goo", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Erik Thunnissen", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Stephen G Swisher", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Giorgio Scagliotti", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Young Tae Kim", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Mariano Provencio", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Prasad Adusumilli", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Yasushi Yatabe", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["John Heymach", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Andrew G Nicholson", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Lukas Bubendorf", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Fred R Hirsch", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Deepali Jain", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Ming Sound Tsao", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Tina Cascone", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Keith Kerr", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Ricardo Oliveira", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Teh-Ying Chou", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Carlos Gil Ferreira", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Lynette Sholl", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Andre Moreira", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Wendy Cooper", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Jamie Chaft", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Johan Vansteenkiste", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Mauro Papotti", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Ugo Pastorino", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Luis Paz-Ares", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Claudia Poleri", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Walter Weder", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Mark Kris", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Tetsuya Mitsudomi", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Fernando Lopez-Rios", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["William D Travis", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Gang Chen", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Ignacio Wistuba", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Hidehito Horinouchi", 2020, "IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY"], ["Alain Tremblay", 2020, "Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study"], ["Martin C Tammemagi", 2020, "Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study"], ["John R Goffin", 2020, "Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study"], ["Sukhinder Atkar-Khattra", 2020, "Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study"], ["Janice L Rudkowski", 2020, "Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study"], ["Michael Johnston", 2020, "Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study"], ["Gregory R Pond", 2020, "Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study"], ["Heidi Schmidt", 2020, "Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study"], ["Stephen Lam", 2020, "Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study"], ["Rick Bhatia", 2020, "Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study"], ["Glen Goss", 2020, "Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study"], ["Simon Martel", 2020, "Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study"], ["Garth Nicholas", 2020, "Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study"], ["Neesha C Dhani", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Judy Quintos", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Katia Tonkin", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Julia V Burnier", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Jean Hurteau", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Gini F Fleming", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Lisa Wang", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Mihaela Cristea", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Daniela Matei", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Suzanne Kamel-Reid", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["John J Wright", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Angela Jain", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Carolyn Johnston", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Stephanie Lheureux", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Marcus O Butler", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Qian Tan", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Koji Matsuo", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Stephen Welch", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Olga Ludkovski", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Hal W Hirte", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Anjali Mehta", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Amit M Oza", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Waldo Jimenez", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Prafull Ghatage", 2020, "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)"], ["Aliya Husain", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Martine Remy-Jardin", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Sonja Klebe", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Sylvie Lantuejoul", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Matthieu Foll", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Valerie W Rusch", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Ian Cree", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Raphael Bueno", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Henry Tazelaar", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Lynnette Fernandez-Cuesta", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Pierre Courtiol", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Jean Michel Vignaud", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Nicolas Girard", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Isabelle Opitz", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Mary Beth Beasley", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Kelly J Butnor", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Paul Baas", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Paul Van Schil", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Loic Lang-Lazdunski", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Thomas Frauenfelder", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Victor Roggli", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Luka Brcic", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Jennifer L Sauter", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Arnaud Scherpereel", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Ritu R Gill", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Maurice Perol", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Samuel G Armato III", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Lucian R Chirieac", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Frank Tirode", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Hedy L Kindler", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Anja Roden", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Birgit Weynand", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Nicolas Alcala", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Harvey Pass", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Allen Gibbs", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Kenzo Hiroshima", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Anna K Nowak", 2020, "EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach"], ["Quincy Chu", 2020, "Amplifying Outcomes: Checkpoint Inhibitor Combinations in First\u2010Line Non\u2010Small Cell Lung Cancer"], ["Vera Hirsh", 2020, "Amplifying Outcomes: Checkpoint Inhibitor Combinations in First\u2010Line Non\u2010Small Cell Lung Cancer"], ["Barbara Melosky", 2020, "Amplifying Outcomes: Checkpoint Inhibitor Combinations in First\u2010Line Non\u2010Small Cell Lung Cancer"], ["Deanna McLeod", 2020, "Amplifying Outcomes: Checkpoint Inhibitor Combinations in First\u2010Line Non\u2010Small Cell Lung Cancer"], ["Paul B Card", 2020, "Amplifying Outcomes: Checkpoint Inhibitor Combinations in First\u2010Line Non\u2010Small Cell Lung Cancer"], ["Natasha Leighl", 2020, "Amplifying Outcomes: Checkpoint Inhibitor Combinations in First\u2010Line Non\u2010Small Cell Lung Cancer"], ["Rosalyn Juergens", 2020, "Amplifying Outcomes: Checkpoint Inhibitor Combinations in First\u2010Line Non\u2010Small Cell Lung Cancer"], ["Ming\u2010Sound Tsao", 2020, "Amplifying Outcomes: Checkpoint Inhibitor Combinations in First\u2010Line Non\u2010Small Cell Lung Cancer"], ["Joella Joseph", 2020, "Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma"], ["Tao Wang", 2020, "Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma"], ["Chang-Qi Zhu", 2020, "Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma"], ["Ming S Tsao", 2019, "Abstract B46: Targeting pancreatic cancer organoids with dual BET and CBP/P300 inhibitor NEO2734"], ["Francis Gilles", 2019, "Abstract B46: Targeting pancreatic cancer organoids with dual BET and CBP/P300 inhibitor NEO2734"], ["Mathieu Lupien", 2019, "Abstract B46: Targeting pancreatic cancer organoids with dual BET and CBP/P300 inhibitor NEO2734"], ["Heewon Seo", 2019, "Abstract B46: Targeting pancreatic cancer organoids with dual BET and CBP/P300 inhibitor NEO2734"], ["Hao Xu", 2019, "Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade"], ["Wei Liu", 2019, "Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade"], ["Hyeonjeong Kang", 2019, "Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade"], ["Ming-sound Tsao", 2019, "Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade"], ["Dalam Ly", 2019, "Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade"], ["Linan Fang", 2019, "Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade"], ["Si-si Wang", 2019, "Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade"], ["Jong Bok Lee", 2019, "Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade"], ["Li Zhang", 2019, "Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade"], ["Junlin Yao", 2019, "Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade"], ["Hongming Pan", 2019, "Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15"], ["Dzana Dervovic", 2019, "Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15"], ["Pierre O Fiset", 2019, "Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population\u2010based reflex testing"], ["Catherine Labb\u00e9", 2019, "Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population\u2010based reflex testing"], ["Adam C Smith", 2019, "Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population\u2010based reflex testing"], ["Hyang\u2010Mi Ko", 2019, "Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population\u2010based reflex testing"], ["Ri Wang", 2019, "Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population\u2010based reflex testing"], ["Kelvin Young", 2019, "Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population\u2010based reflex testing"], ["Scott L Boerner", 2019, "Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population\u2010based reflex testing"], ["Natasha B Leighl", 2019, "Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population\u2010based reflex testing"], ["Melania Pintilie", 2019, "Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population\u2010based reflex testing"], ["Emina Torlakovic", 2019, "Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population\u2010based reflex testing"], ["Carol Cheung", 2019, "Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population\u2010based reflex testing"], ["Gilda da Cunha Santos", 2019, "Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population\u2010based reflex testing"], ["Kenneth J Craddock", 2019, "Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population\u2010based reflex testing"], ["Jeffrey Tanguay", 2019, "Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population\u2010based reflex testing"], ["David M Hwang", 2019, "Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population\u2010based reflex testing"], ["Tadashi Ishii", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Tetsuya Akaishi", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Yoshinori Okada", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Takahiro Mimori", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Mie Yamanaka", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Masakazu Ichinose", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Naoto Ishii", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Atsuko Asao", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Masao Nagasaki", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Michiaki Abe", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Kota Ishizawa", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Seiichi Kobayashi", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Yuriko Saiki", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Riu Yamashita", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Akira Horii", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Ryota Saito", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Yutaka Tojo", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Shinichi Fukushige", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Akira Sakurada", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["Eisaku Miyauchi", 2019, "CD45+ CD326+ Cells are Predictive of Poor Prognosis in Non\u2013Small Cell Lung Cancer Patients"], ["J Yannis Perentes", 2019, "Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma"], ["Trevor D McKee", 2019, "Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma"], ["Mikihiro Kohno", 2019, "Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma"], ["Laura Donahoe", 2019, "Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma"], ["Penelope Bradbury", 2019, "Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma"], ["Licun Wu", 2019, "Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma"], ["Junichi Murakami", 2019, "Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma"], ["Mei-Lin Chan", 2019, "Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma"], ["BC John Cho", 2019, "Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma"], ["Marc de Perrot", 2019, "Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma"], ["Shaf Keshavjee", 2019, "Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma"], ["Dorothy J Giroux", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["Marcin Ostrowski", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["Fran\u00e7oise Galateau-Sall\u00e9", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["Maurizio Infante", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["Edith Marom", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["Lynn Shemanski", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["Mirella Marino", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["Hans Hoffman", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["John Crowley", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["Paul van Schil", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["Jessica Donnington", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["Jun Nakajima", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["Kari Chansky", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["John G Edwards", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["Ram\u00f3n Rami-Porta", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["Elisabeth Brambilla", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["Souheil Boubia", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["Marc Krasnik", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["Hisao Asamura", 2019, "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer"], ["Kenneth Aldape", 2019, "COMPREHENSIVE METHYLOME ANALYSIS OF EGFR-MUTANT PRIMARY LUNG ADENOCARCINOMA AND MATCHED BRAIN METASTASIS"], ["Gelareh Zadeh", 2019, "COMPREHENSIVE METHYLOME ANALYSIS OF EGFR-MUTANT PRIMARY LUNG ADENOCARCINOMA AND MATCHED BRAIN METASTASIS"], ["Shirin Karimi", 2019, "COMPREHENSIVE METHYLOME ANALYSIS OF EGFR-MUTANT PRIMARY LUNG ADENOCARCINOMA AND MATCHED BRAIN METASTASIS"], ["Hadas Sorotsky", 2019, "COMPREHENSIVE METHYLOME ANALYSIS OF EGFR-MUTANT PRIMARY LUNG ADENOCARCINOMA AND MATCHED BRAIN METASTASIS"], ["Jessica Weiss", 2019, "COMPREHENSIVE METHYLOME ANALYSIS OF EGFR-MUTANT PRIMARY LUNG ADENOCARCINOMA AND MATCHED BRAIN METASTASIS"], ["Yasin Mamatjan", 2019, "COMPREHENSIVE METHYLOME ANALYSIS OF EGFR-MUTANT PRIMARY LUNG ADENOCARCINOMA AND MATCHED BRAIN METASTASIS"], ["Jeffrey Zuccato", 2019, "COMPREHENSIVE METHYLOME ANALYSIS OF EGFR-MUTANT PRIMARY LUNG ADENOCARCINOMA AND MATCHED BRAIN METASTASIS"], ["Frances Shepherd", 2019, "COMPREHENSIVE METHYLOME ANALYSIS OF EGFR-MUTANT PRIMARY LUNG ADENOCARCINOMA AND MATCHED BRAIN METASTASIS"], ["Scott Tsai", 2019, "Prediction of lung cancer risk at follow-up screening with low-dose CT: a training and validation study of a deep learning method"], ["Daria Manos", 2019, "Prediction of lung cancer risk at follow-up screening with low-dose CT: a training and validation study of a deep learning method"], ["Michel Gingras", 2019, "Prediction of lung cancer risk at follow-up screening with low-dose CT: a training and validation study of a deep learning method"], ["Cheng T Lin", 2019, "Prediction of lung cancer risk at follow-up screening with low-dose CT: a training and validation study of a deep learning method"], ["Yuliang Li", 2019, "Prediction of lung cancer risk at follow-up screening with low-dose CT: a training and validation study of a deep learning method"], ["Yanxun Xu", 2019, "Prediction of lung cancer risk at follow-up screening with low-dose CT: a training and validation study of a deep learning method"], ["Peng Huang", 2019, "Prediction of lung cancer risk at follow-up screening with low-dose CT: a training and validation study of a deep learning method"], ["Ping Hu", 2019, "Prediction of lung cancer risk at follow-up screening with low-dose CT: a training and validation study of a deep learning method"], ["John R Mayo", 2019, "Prediction of lung cancer risk at follow-up screening with low-dose CT: a training and validation study of a deep learning method"], ["Lori Stewart", 2019, "Prediction of lung cancer risk at follow-up screening with low-dose CT: a training and validation study of a deep learning method"], ["Malcolm V Brock", 2019, "Prediction of lung cancer risk at follow-up screening with low-dose CT: a training and validation study of a deep learning method"], ["Jean M Seely", 2019, "Prediction of lung cancer risk at follow-up screening with low-dose CT: a training and validation study of a deep learning method"], ["Sergio Pasian", 2019, "Prediction of lung cancer risk at follow-up screening with low-dose CT: a training and validation study of a deep learning method"], ["Paul Burrowes", 2019, "Prediction of lung cancer risk at follow-up screening with low-dose CT: a training and validation study of a deep learning method"], ["Christian Couture", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Catherine Ross", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Gabor Fischer", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Diana Ionescu", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["C Blake Gilks", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Penny Barnes", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Hangjun Wang", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["John Garratt", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Paul E Swanson", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Laurette Geldenhuys", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Alan Spatz", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Jean Deschenes", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Emina E Torlakovic", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Lisa Manning", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Hyun J Lim", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Hala El-Zimaity", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Robert Riddell", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Sinchita Roy-Chowdhuri", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Marius Ilie", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Victor A Tron", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Adnan Mansoor", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Gilbert Bigras", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Carol C Cheung", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Jagdish Butany", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Fiorella Calabrese", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Zhaolin Xu", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Scott Boerner", 2019, "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association \u2026"], ["Dongsheng Tu", 2019, "A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2\u2010Positive Metastatic Breast Cancer (CCTG IND. 229)"], ["Stephen Chia", 2019, "A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2\u2010Positive Metastatic Breast Cancer (CCTG IND. 229)"], ["Eitan Amir", 2019, "A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2\u2010Positive Metastatic Breast Cancer (CCTG IND. 229)"], ["Rachel Goodwin", 2019, "A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2\u2010Positive Metastatic Breast Cancer (CCTG IND. 229)"], ["Karen Gelmon", 2019, "A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2\u2010Positive Metastatic Breast Cancer (CCTG IND. 229)"], ["Lesley Seymour", 2019, "A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2\u2010Positive Metastatic Breast Cancer (CCTG IND. 229)"], ["Diego Villa", 2019, "A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2\u2010Positive Metastatic Breast Cancer (CCTG IND. 229)"], ["Phillipe L Bedard", 2019, "A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2\u2010Positive Metastatic Breast Cancer (CCTG IND. 229)"], ["John Hilton", 2019, "A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2\u2010Positive Metastatic Breast Cancer (CCTG IND. 229)"], ["E Pasko", 2018, "P3. 03-19 The Lysyl Oxidase like-1 Promotes NSCLC Tumorigenecity Through Increased Matrix Reorganization and Stiffness"], ["C Zeltz", 2018, "P3. 03-19 The Lysyl Oxidase like-1 Promotes NSCLC Tumorigenecity Through Increased Matrix Reorganization and Stiffness"], ["R Navab", 2018, "P3. 03-19 The Lysyl Oxidase like-1 Promotes NSCLC Tumorigenecity Through Increased Matrix Reorganization and Stiffness"], ["M Tsao", 2018, "P3. 03-19 The Lysyl Oxidase like-1 Promotes NSCLC Tumorigenecity Through Increased Matrix Reorganization and Stiffness"], ["H Notsuda", 2018, "MA27. 07 Lung Adenocarcinoma Harboring BRAF G469V Mutation is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors"], ["Z Fang", 2018, "MA27. 07 Lung Adenocarcinoma Harboring BRAF G469V Mutation is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors"], ["M Ikura", 2018, "MA27. 07 Lung Adenocarcinoma Harboring BRAF G469V Mutation is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors"], ["M Li", 2018, "MA27. 07 Lung Adenocarcinoma Harboring BRAF G469V Mutation is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors"], ["N Liu", 2018, "MA27. 07 Lung Adenocarcinoma Harboring BRAF G469V Mutation is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors"], ["V Raghavan", 2018, "MA27. 07 Lung Adenocarcinoma Harboring BRAF G469V Mutation is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors"], ["N Pham", 2018, "MA27. 07 Lung Adenocarcinoma Harboring BRAF G469V Mutation is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors"], ["N Moghal", 2018, "MA27. 07 Lung Adenocarcinoma Harboring BRAF G469V Mutation is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors"], ["C Marshall", 2018, "MA27. 07 Lung Adenocarcinoma Harboring BRAF G469V Mutation is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors"], ["W Franklin", 2018, "P2. 09-01 Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma"], ["D Harpole", 2018, "P2. 09-01 Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma"], ["F Hirsch", 2018, "P2. 09-01 Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma"], ["M Watson", 2018, "P2. 09-01 Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma"], ["R Bueno", 2018, "P2. 09-01 Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma"], ["L Chirieac", 2018, "P2. 09-01 Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma"], ["A Bokhoven", 2018, "P2. 09-01 Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma"], ["W Richards", 2018, "P2. 09-01 Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma"], ["H Yu", 2018, "P2. 09-01 Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma"], ["C Rivard", 2018, "P2. 09-01 Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma"], ["D Merrick", 2018, "P2. 09-01 Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma"], ["C Zhu", 2018, "MTE01. 02 Lung Patient Derived Xenograft and Organoid"], ["D Ravi", 2018, "MTE01. 02 Lung Patient Derived Xenograft and Organoid"], ["D Wang", 2018, "MTE01. 02 Lung Patient Derived Xenograft and Organoid"], ["N Leighl", 2018, "MTE01. 02 Lung Patient Derived Xenograft and Organoid"], ["J Weiss", 2018, "MTE01. 02 Lung Patient Derived Xenograft and Organoid"], ["L Tamblyn", 2018, "MTE01. 02 Lung Patient Derived Xenograft and Organoid"], ["L Li", 2018, "MTE01. 02 Lung Patient Derived Xenograft and Organoid"], ["Q Li", 2018, "MTE01. 02 Lung Patient Derived Xenograft and Organoid"], ["G Liu", 2018, "MTE01. 02 Lung Patient Derived Xenograft and Organoid"], ["M Pintilie", 2018, "MTE01. 02 Lung Patient Derived Xenograft and Organoid"], ["N Radulovich", 2018, "MTE01. 02 Lung Patient Derived Xenograft and Organoid"], ["S Martins-Filho", 2018, "MTE01. 02 Lung Patient Derived Xenograft and Organoid"], ["J Tong", 2018, "MTE01. 02 Lung Patient Derived Xenograft and Organoid"], ["F Shepherd", 2018, "MTE01. 02 Lung Patient Derived Xenograft and Organoid"], ["E Stewart", 2018, "MTE01. 02 Lung Patient Derived Xenograft and Organoid"], ["M Moran", 2018, "MTE01. 02 Lung Patient Derived Xenograft and Organoid"], ["R Shi", 2018, "MTE01. 02 Lung Patient Derived Xenograft and Organoid"], ["M Moskovitz", 2018, "MA25. 11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT"], ["D Torti", 2018, "MA25. 11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT"], ["M Cabanero", 2018, "MA25. 11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT"], ["G Zadeh", 2018, "MA25. 11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT"], ["T Pugh", 2018, "MA25. 11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT"], ["J Torchia", 2018, "MA25. 11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT"], ["M Doherty", 2018, "MA25. 11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT"], ["J So", 2018, "MA25. 11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT"], ["P Bradbury", 2018, "MA25. 11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT"], ["F Moraes", 2018, "MA25. 11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT"], ["H Sorotsky", 2018, "MA25. 11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT"], ["D Shultz", 2018, "MA25. 11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT"], ["A Kia", 2018, "MA25. 11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT"], ["V Sugumar", 2018, "MA25. 11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT"], ["B Lok", 2018, "MA25. 11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT"], ["G Pond", 2018, "P2. 11-23 Risk Perception Among a Lung Cancer Screening Population"], ["S Puksa", 2018, "P2. 11-23 Risk Perception Among a Lung Cancer Screening Population"], ["S Martel", 2018, "P2. 11-23 Risk Perception Among a Lung Cancer Screening Population"], ["H Schmidt", 2018, "P2. 11-23 Risk Perception Among a Lung Cancer Screening Population"], ["A Tremblay", 2018, "P2. 11-23 Risk Perception Among a Lung Cancer Screening Population"], ["G Nicholas", 2018, "P2. 11-23 Risk Perception Among a Lung Cancer Screening Population"], ["M Tammemagi", 2018, "P2. 11-23 Risk Perception Among a Lung Cancer Screening Population"], ["J Turner", 2018, "P2. 11-23 Risk Perception Among a Lung Cancer Screening Population"], ["S Atkar-Khattra", 2018, "P2. 11-23 Risk Perception Among a Lung Cancer Screening Population"], ["R Bhatia", 2018, "P2. 11-23 Risk Perception Among a Lung Cancer Screening Population"], ["J Goffin", 2018, "P2. 11-23 Risk Perception Among a Lung Cancer Screening Population"], ["S Lam", 2018, "P2. 11-23 Risk Perception Among a Lung Cancer Screening Population"], ["G Goss", 2018, "P2. 11-23 Risk Perception Among a Lung Cancer Screening Population"], ["M Johnston", 2018, "P2. 11-23 Risk Perception Among a Lung Cancer Screening Population"], ["I Wistuba", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["M Mino-Kenudson", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["J Sauter", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["Johan Botling", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["Y Yatabe", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["MB Beasley", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["C Poleri", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["A Moreira", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["E Thunnissen", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["P Russell", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["S Lantuejoul", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["A Nicholson", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["K Kerr", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["M Noguchi", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["G Chen", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["J Chung", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["L Bubendorf", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["T Chou", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["M Wynes", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["A Borczuk", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["S Dacic", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["G Pelosi", 2018, "OA03. 03 phase 2B of Blueprint PD-L1 immunohistochemistry assay comparability study"], ["J Mcconnell", 2018, "MA27. 01 Establishment of PDX From Tumors Characterized by EGFR Mutations or ALK Fusion Genes from Resections, Biopsies and Pleural Fluids"], ["K Yasufuku", 2018, "MA27. 01 Establishment of PDX From Tumors Characterized by EGFR Mutations or ALK Fusion Genes from Resections, Biopsies and Pleural Fluids"], ["D Patel", 2018, "MA27. 01 Establishment of PDX From Tumors Characterized by EGFR Mutations or ALK Fusion Genes from Resections, Biopsies and Pleural Fluids"], ["A Grindlay", 2018, "MA27. 01 Establishment of PDX From Tumors Characterized by EGFR Mutations or ALK Fusion Genes from Resections, Biopsies and Pleural Fluids"], ["F Allison", 2018, "MA27. 01 Establishment of PDX From Tumors Characterized by EGFR Mutations or ALK Fusion Genes from Resections, Biopsies and Pleural Fluids"], ["M Lupien", 2018, "MA27. 03 Multi-Omic Characterization of TKI-Treated Drug-Tolerant Cell Population in an EGFR-Mutated NSCLC Primary-Derived Xenograft"], ["T Li", 2018, "MA27. 03 Multi-Omic Characterization of TKI-Treated Drug-Tolerant Cell Population in an EGFR-Mutated NSCLC Primary-Derived Xenograft"], ["J Bruce", 2018, "MA27. 03 Multi-Omic Characterization of TKI-Treated Drug-Tolerant Cell Population in an EGFR-Mutated NSCLC Primary-Derived Xenograft"], ["SY Shen", 2018, "MA27. 03 Multi-Omic Characterization of TKI-Treated Drug-Tolerant Cell Population in an EGFR-Mutated NSCLC Primary-Derived Xenograft"], ["P Guilhamon", 2018, "MA27. 03 Multi-Omic Characterization of TKI-Treated Drug-Tolerant Cell Population in an EGFR-Mutated NSCLC Primary-Derived Xenograft"], ["R Singhania", 2018, "MA27. 03 Multi-Omic Characterization of TKI-Treated Drug-Tolerant Cell Population in an EGFR-Mutated NSCLC Primary-Derived Xenograft"], ["D De Carvalho", 2018, "MA27. 03 Multi-Omic Characterization of TKI-Treated Drug-Tolerant Cell Population in an EGFR-Mutated NSCLC Primary-Derived Xenograft"], ["J Kuo", 2018, "MA24. 05 Baseline Spatial Heterogeneity of T790M in Tyrosine Kinase Inhibitor Na\u00efve EGFR-Mutant Lung Adenocarcinomas"], ["D Ly", 2018, "P1. 04-05 Elucidating the Role of Leukocyte-Associated Immunoglobin-Like Receptor 2 (LAIR2) in Lung Cancer Development"], ["L Zhang", 2018, "P1. 04-05 Elucidating the Role of Leukocyte-Associated Immunoglobin-Like Receptor 2 (LAIR2) in Lung Cancer Development"], ["K Ballman", 2018, "P1. 04-23 Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma"], ["M Herman", 2018, "P1. 04-23 Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma"], ["Z Chen", 2018, "P1. 04-23 Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma"], ["D Beer", 2018, "P1. 04-23 Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma"], ["R Govindan", 2018, "P1. 04-23 Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma"], ["D Gandara", 2018, "P1. 04-23 Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma"], ["M Joshi", 2018, "P1. 04-23 Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma"], ["P Reis", 2018, "P2. 11-19 MicroRNAs as Liquid Biopsy Biomarkers for Early Detection in Lung Cancer."], ["I Jurisica", 2018, "P2. 11-19 MicroRNAs as Liquid Biopsy Biomarkers for Early Detection in Lung Cancer."], ["Ravi Menezes", 2018, "Importance of long-term low-dose CT follow-up after negative findings at previous lung cancer screening"], ["Grainne M O\u2019Kane", 2018, "Importance of long-term low-dose CT follow-up after negative findings at previous lung cancer screening"], ["Frances A Shepherd", 2018, "Importance of long-term low-dose CT follow-up after negative findings at previous lung cancer screening"], ["Maureen McGregor", 2018, "Importance of long-term low-dose CT follow-up after negative findings at previous lung cancer screening"], ["John Kavanagh", 2018, "Importance of long-term low-dose CT follow-up after negative findings at previous lung cancer screening"], ["Tracy Stockley", 2018, "P2. 03-04 Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience"], ["T Zhang", 2018, "P2. 03-04 Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience"], ["M Shabir", 2018, "P2. 03-04 Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience"], ["L Le", 2018, "P2. 03-04 Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience"], ["Kirstin Perdrizet", 2018, "P2. 03-04 Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience"], ["S Kamel-Reid", 2018, "P2. 03-04 Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience"], ["David Hwang", 2018, "P2. 03-04 Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience"], ["A Sacher", 2018, "P2. 03-04 Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience"], ["J Law", 2018, "P2. 03-04 Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience"], ["M Sawczak", 2018, "P2. 03-04 Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience"], ["Prodipto Pal", 2018, "P2. 03-04 Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience"], ["Paul Brennan", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Christopher I Amos", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Miodrag Ognjanovic", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Guillermo Fernandez-Tardon", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["M Dawn Teare", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["David Christiani", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Younghun Han", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Anush Mukeriya", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Ghislaine Scelo", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Simona Ognjanovic", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Albert Rosenberger", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Gary Goodman", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Hongbing Shen", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Aida Ferreiro-Iglesias", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Adonina Tardon", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Ciprian Bolca", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Aage Haugen", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Lambertus A Kiemeney", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Xuchen Zong", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Ahsan Kamal", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Dakai Zhu", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Xifeng Wu", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Stig Egil Bojesen", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Jennifer Doherty", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Yafang Li", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Jolanta Lissowska", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Demetrios Albanes", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Beata Swiatkowska", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Penella Woll", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Angeline Andrew", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Juncheng Dai", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["James McKay", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Ma\u0142gorzata Szo\u0142kowska", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Kjell Grankvist", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Maria Teresa Landi", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Jian-Min Yuan", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Stacey Slone", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Shanbeh Zienolddiny", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Milica Kontic", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["John K Field", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Corina Lesseur", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["David C Qian", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["David Zaridze", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Xuemei Ji", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Milan Savic", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Ana Fernandez-Somoano", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Xiangjun Xiao", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Michael Davies", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Erik HFM van der Heijden", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Mattias Johansson", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Susanne Arnold", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Rayjean J Hung", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Yun-Chul Hong", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Neil Caporaso", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Loic Le Marchand", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Jinyoung Byun", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Gadi Rennert", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Matthew B Schabath", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Philip Lazarus", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Heike Bickeb\u00f6ller", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Angela Risch", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Vladimir Janout", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Olle Melander", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Ivana Holcatova", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Hans Brunnstr\u00f6m", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Chu Chen", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Melinda C Aldrich", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Eric Duell", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Mikael Johansson", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["H-Erich Wichmann", 2018, "Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity"], ["Shiyan Wang", 2018, "Refined RIP-seq protocol for epitranscriptome analysis with low input materials"], ["Musadeqque Ahmed", 2018, "Refined RIP-seq protocol for epitranscriptome analysis with low input materials"], ["Junjie Tony Hua", 2018, "Refined RIP-seq protocol for epitranscriptome analysis with low input materials"], ["Fraser Soares", 2018, "Refined RIP-seq protocol for epitranscriptome analysis with low input materials"], ["Yong Zeng", 2018, "Refined RIP-seq protocol for epitranscriptome analysis with low input materials"], ["Miranda Wang", 2018, "Refined RIP-seq protocol for epitranscriptome analysis with low input materials"], ["Housheng Hansen He", 2018, "Refined RIP-seq protocol for epitranscriptome analysis with low input materials"], ["Shanshan Gao", 2018, "Refined RIP-seq protocol for epitranscriptome analysis with low input materials"], ["Michael F Moran", 2018, "Refined RIP-seq protocol for epitranscriptome analysis with low input materials"], ["Jiansheng Guan", 2018, "Refined RIP-seq protocol for epitranscriptome analysis with low input materials"], ["Haiyang Guo", 2018, "Refined RIP-seq protocol for epitranscriptome analysis with low input materials"], ["Richard Tomasini", 2018, "TAp73 regulates the spindle assembly check-point by modulating BubR1 activity (vol 106, pg 797, 2009)"], ["Suzanne K Lau", 2018, "TAp73 regulates the spindle assembly check-point by modulating BubR1 activity (vol 106, pg 797, 2009)"], ["Katsuya Tsuchihara", 2018, "TAp73 regulates the spindle assembly check-point by modulating BubR1 activity (vol 106, pg 797, 2009)"], ["Chiharu Tsuda", 2018, "TAp73 regulates the spindle assembly check-point by modulating BubR1 activity (vol 106, pg 797, 2009)"], ["Andrea Jurisicova", 2018, "TAp73 regulates the spindle assembly check-point by modulating BubR1 activity (vol 106, pg 797, 2009)"], ["Margareta Wilhelm", 2018, "TAp73 regulates the spindle assembly check-point by modulating BubR1 activity (vol 106, pg 797, 2009)"], ["Alessandro Rufini", 2018, "TAp73 regulates the spindle assembly check-point by modulating BubR1 activity (vol 106, pg 797, 2009)"], ["Tak W Mak", 2018, "TAp73 regulates the spindle assembly check-point by modulating BubR1 activity (vol 106, pg 797, 2009)"], ["Juan L Iovanna", 2018, "TAp73 regulates the spindle assembly check-point by modulating BubR1 activity (vol 106, pg 797, 2009)"], ["Gerry Melino", 2018, "TAp73 regulates the spindle assembly check-point by modulating BubR1 activity (vol 106, pg 797, 2009)"], ["Emman Mascari\u00f1as", 2018, "Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway"], ["Morgan Barron", 2018, "Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway"], ["Kevin Adrian", 2018, "Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway"], ["Georgina Mancinelli", 2018, "Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway"], ["Paul J Grippo", 2018, "Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway"], ["Mireille Wojtanek", 2018, "Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway"], ["Michael Heiferman", 2018, "Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway"], ["Andrew M Diaz", 2018, "Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway"], ["Brian DeCant", 2018, "Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway"], ["Sambasiva Rao", 2018, "Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway"], ["Yongzeng Ding", 2018, "Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway"], ["Ronald McKinney", 2018, "Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway"], ["Michel Ouellette", 2018, "Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway"], ["Bhargava Mullapudi", 2018, "Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway"], ["Michelle Schultz", 2018, "Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway"], ["Carolina Torres", 2018, "Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway"], ["David J Bentrem", 2018, "Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway"], ["Gregorz J Korpanty", 2018, "The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer"], ["Kevin Jao", 2018, "The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer"], ["Ronald Feld", 2018, "The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer"], ["Penelope A Bradbury", 2018, "The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer"], ["C\u00e9line Mascaux", 2018, "The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer"], ["Pascale Tomasini", 2018, "The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer"], ["Shingo Sakashita", 2018, "The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer"], ["Mary-Beth Beasley", 2018, "PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project"], ["Hui Yu", 2018, "PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project"], ["Keith M Kerr", 2018, "PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project"], ["Prudence A Russell", 2018, "PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project"], ["Lucian Chirieac", 2018, "PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project"], ["Murry W Wynes", 2018, "PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project"], ["Alain C Borczuk", 2018, "PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project"], ["Jennifer Sauter", 2018, "PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project"], ["Mark Kockx", 2018, "PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project"], ["Andre L Moreira", 2018, "PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project"], ["Mari Mino-Kenudson", 2018, "PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project"], ["Masayuki Noguchi", 2018, "PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project"], ["Jin-Haeng Chung", 2018, "PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project"], ["Grzegorz J Korpanty", 2018, "A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND. 210, a Canadian cancer trials group trial"], ["Harriet Feilotter", 2018, "A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND. 210, a Canadian cancer trials group trial"], ["Haji Chalchal", 2018, "A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND. 210, a Canadian cancer trials group trial"], ["Thierry Alcindor", 2018, "A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND. 210, a Canadian cancer trials group trial"], ["Stephen A Welch", 2018, "A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND. 210, a Canadian cancer trials group trial"], ["Patricia A Tang", 2018, "A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND. 210, a Canadian cancer trials group trial"], ["Timothy Asmis", 2018, "A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND. 210, a Canadian cancer trials group trial"], ["Derek J Jonker", 2018, "A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND. 210, a Canadian cancer trials group trial"], ["Yoo-Joung Ko", 2018, "A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND. 210, a Canadian cancer trials group trial"], ["Ashley Theis", 2018, "A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND. 210, a Canadian cancer trials group trial"], ["Eric X Chen", 2018, "A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND. 210, a Canadian cancer trials group trial"], ["Anna Tomiak", 2018, "A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND. 210, a Canadian cancer trials group trial"], ["Howard Lim", 2018, "A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND. 210, a Canadian cancer trials group trial"], ["Hagen Kennecke", 2018, "A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND. 210, a Canadian cancer trials group trial"], ["M Christine Cripps", 2018, "A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND. 210, a Canadian cancer trials group trial"], ["Christopher Haiman", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Yohan Boss\u00e9", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Yu-Tang Gao", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Martin D Tobin", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Olga Gorlova", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["David Qian", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Li Su", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Eric J Duell", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["David C Christiani", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Lei Song", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Thomas Muley", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Michael W Marcus", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Antonia Trichopoulou", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Kim Overvad", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Fiona Taylor", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Maxime Lamontagne", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Irene Br\u00fcske", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Zhibin Hu", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Louise V Wain", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Richard Houlston", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Victoria Stevens", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Lynne Wilkens", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Jiang Gui", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Fangyi Gu", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Ma\u2019en Obeidat", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Lesley M Butler", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Ivan Gorlov", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Angela C Pesatori", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Gary E Goodman", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["William S Bush", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Ruyang Zhang", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Susanne M Arnold", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Woon-Puay Koh", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Robert Carreras-Torres", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["David C Nickle", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Angeline S Andrew", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Nancy Diao", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Bin Zhu", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Vidar Skaug", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Per Bakke", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Jin Hee Kim", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Jakob S Johansen", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Wim Timens", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Stephen Chanock", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Mariella de Biasi", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Wei-Qi Wei", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Rosario Tumino", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Yonathan Brhane", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Rachel F Tyndale", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Judith Manz", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Walid Saliba", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Angela Cox", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Yuanqing Ye", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Jonas Manjer", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Anders Mellemgaard", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Anush Mukeria", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Michael PA Davies", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Gad Rennert", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Eric B Haura", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Mar\u00eda Soler Artigas", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Pier A Bertazzi", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Tadeusz M Orlowski", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["David C Muller", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["John McLaughlin", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Stig E Bojesen", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["Philippe Joubert", 2018, "Identification of susceptibility pathways for the role of chromosome 15q25. 1 in modifying lung cancer risk"], ["F Galateau Salle", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["A Gibbs", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["N Le Stang", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["VL Roggli", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["JM Vignaud", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["JM Picquenot", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["A Churg", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["A Scherpereel", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["F Thivolet", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["I Rouquette", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["R Attanoos", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["AG Nicholson", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["A Foulet-Roge", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["H Begueret", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["A Marchevsky", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["MS Tsao", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["HD Tazelaar", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["D Pissaloux", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["B Weynand", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["JC Pairon", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["JL Sauter", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["V Hofman", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["S Giusiano-Courcambeck", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["V Rusch", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["C Danel", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["K Nabeshima", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["F Capron", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["MC Copin", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["N Girard", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["S Klebe", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["K Hiroshima", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["C Sagan", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["WD Travis", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["F Damiola", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["AN Husain", 2018, "New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center"], ["Yuzhe Zhang", 2018, "Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19"], ["Shannon K McDonnell", 2018, "Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19"], ["Felix Y Feng", 2018, "Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19"], ["Musaddeque Ahmed", 2018, "Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19"], ["Parasvi S Patel", 2018, "Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19"], ["Yi Liang", 2018, "Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19"], ["Stephen N Thibodeau", 2018, "Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19"], ["Sujun Chen", 2018, "Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19"], ["Hui Li", 2018, "Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19"], ["Nicholas B Larson", 2018, "Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19"], ["Cindy Q Yao", 2018, "Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19"], ["Stanley Zhou", 2018, "Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19"], ["Paul C Boutros", 2018, "Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19"], ["Amina Zoubeidi", 2018, "Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19"], ["Theodorus van der Kwast", 2018, "Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19"], ["Jennifer Lu", 2018, "Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19"], ["Mark Zaidi", 2018, "Oxygen metabolism and hypoxia tolerance in organoid models of pancreatic ductal adenocarcinoma"], ["David Hedley", 2018, "Oxygen metabolism and hypoxia tolerance in organoid models of pancreatic ductal adenocarcinoma"], ["Marianne Koritzinsky", 2018, "Oxygen metabolism and hypoxia tolerance in organoid models of pancreatic ductal adenocarcinoma"], ["Bradly G Wouters", 2018, "Oxygen metabolism and hypoxia tolerance in organoid models of pancreatic ductal adenocarcinoma"], ["Dan Cojocari", 2018, "Oxygen metabolism and hypoxia tolerance in organoid models of pancreatic ductal adenocarcinoma"], ["Trevor McKee", 2018, "Oxygen metabolism and hypoxia tolerance in organoid models of pancreatic ductal adenocarcinoma"], ["Qingquan Liu", 2018, "Oxygen metabolism and hypoxia tolerance in organoid models of pancreatic ductal adenocarcinoma"], ["Ji Zhang", 2018, "Oxygen metabolism and hypoxia tolerance in organoid models of pancreatic ductal adenocarcinoma"], ["Michael Ohh", 2018, "Altering the regulation of KRAS GTPase cycle via Src and SHP2 creates a potential therapeutic vulnerability for pancreatic cancer"], ["Christopher B Marshall", 2018, "Altering the regulation of KRAS GTPase cycle via Src and SHP2 creates a potential therapeutic vulnerability for pancreatic cancer"], ["Yoshihito Kano", 2018, "Altering the regulation of KRAS GTPase cycle via Src and SHP2 creates a potential therapeutic vulnerability for pancreatic cancer"], ["Teklab Gebregiworgis", 2018, "Altering the regulation of KRAS GTPase cycle via Src and SHP2 creates a potential therapeutic vulnerability for pancreatic cancer"], ["Mitsuhiko Ikura", 2018, "Altering the regulation of KRAS GTPase cycle via Src and SHP2 creates a potential therapeutic vulnerability for pancreatic cancer"], ["Corey J Langer", 2018, "Radiologic Pseudoprogression during Anti\u2013PD-1 Therapy for Advanced Non\u2013Small Cell Lung Cancer"], ["Jeffrey C Thompson", 2018, "Radiologic Pseudoprogression during Anti\u2013PD-1 Therapy for Advanced Non\u2013Small Cell Lung Cancer"], ["Mark Hammer", 2018, "Radiologic Pseudoprogression during Anti\u2013PD-1 Therapy for Advanced Non\u2013Small Cell Lung Cancer"], ["Stephen J Bagley", 2018, "Radiologic Pseudoprogression during Anti\u2013PD-1 Therapy for Advanced Non\u2013Small Cell Lung Cancer"], ["Charu Aggarwal", 2018, "Radiologic Pseudoprogression during Anti\u2013PD-1 Therapy for Advanced Non\u2013Small Cell Lung Cancer"], ["Arun C Nachiappan", 2018, "Radiologic Pseudoprogression during Anti\u2013PD-1 Therapy for Advanced Non\u2013Small Cell Lung Cancer"], ["Charles B Simone II", 2018, "Radiologic Pseudoprogression during Anti\u2013PD-1 Therapy for Advanced Non\u2013Small Cell Lung Cancer"], ["Joshua M Bauml", 2018, "Radiologic Pseudoprogression during Anti\u2013PD-1 Therapy for Advanced Non\u2013Small Cell Lung Cancer"], ["Sharyn I Katz", 2018, "Radiologic Pseudoprogression during Anti\u2013PD-1 Therapy for Advanced Non\u2013Small Cell Lung Cancer"], ["Ju-Yoon Yoon", 2018, "The eighth TNM classification for lung cancer\u2014What is next?"], ["Christina Sit", 2018, "Translation of Knowledge to Practice\u2014Improving Awareness in NSCLC Molecular Testing"], ["Milan Patel", 2018, "Translation of Knowledge to Practice\u2014Improving Awareness in NSCLC Molecular Testing"], ["Manjula Maganti", 2018, "Translation of Knowledge to Practice\u2014Improving Awareness in NSCLC Molecular Testing"], ["Matthew Binnie", 2018, "Translation of Knowledge to Practice\u2014Improving Awareness in NSCLC Molecular Testing"], ["Tom Waddell", 2018, "Translation of Knowledge to Practice\u2014Improving Awareness in NSCLC Molecular Testing"], ["Alona Zer", 2018, "Translation of Knowledge to Practice\u2014Improving Awareness in NSCLC Molecular Testing"], ["Anthony Brade", 2018, "Translation of Knowledge to Practice\u2014Improving Awareness in NSCLC Molecular Testing"], ["Tae Bong Chung", 2018, "Translation of Knowledge to Practice\u2014Improving Awareness in NSCLC Molecular Testing"], ["Ron F Carter", 2018, "Translation of Knowledge to Practice\u2014Improving Awareness in NSCLC Molecular Testing"], ["Mike Sung", 2018, "Translation of Knowledge to Practice\u2014Improving Awareness in NSCLC Molecular Testing"], ["Harman Sekhon", 2018, "Translation of Knowledge to Practice\u2014Improving Awareness in NSCLC Molecular Testing"], ["Jean Claude Cutz", 2018, "Translation of Knowledge to Practice\u2014Improving Awareness in NSCLC Molecular Testing"], ["Narinder Paul", 2018, "Translation of Knowledge to Practice\u2014Improving Awareness in NSCLC Molecular Testing"], ["Paulo Nuin", 2018, "Correction to: Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections."], ["Andrew Evans", 2018, "Correction to: Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections."], ["Ciro Pereira", 2018, "Correction to: Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections."], ["Jean McGowan-Jordan", 2018, "Correction to: Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections."], ["Robert J Gooding", 2018, "Correction to: Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections."], ["Maisa Yoshimoto", 2018, "Correction to: Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections."], ["Jeremy A Squire", 2018, "Correction to: Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections."], ["Alexander Boag", 2018, "Correction to: Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections."], ["Jennifer Good", 2018, "Correction to: Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections."], ["DN Ionescu", 2018, "Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective"], ["MR Downes", 2018, "Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective"], ["A Christofides", 2018, "Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective"], ["Thierry Le-Chevalier", 2018, "Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer"], ["Federico Rotolo", 2018, "Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer"], ["Jean-Pierre Pignon", 2018, "Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer"], ["Stephen L Graziano", 2018, "Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer"], ["Ken Olaussen", 2018, "Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer"], ["Stefan Michiels", 2018, "Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer"], ["Jean-Charles Soria", 2018, "Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer"], ["Robert Kratzke", 2018, "Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer"], ["James D Brierley", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Dong Kwan Kim", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Giuseppe Giaccone", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["David Beer", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Hui Liu", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Gustavo Lyons", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Fran\u00e7oise Galateau-Salle", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Paul Martin Putora", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Luis Montuenga", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Raymond U Osarogiagbon", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Heber MacMahon", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Luiz Henrique Araujo", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Vanessa Bolejack", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Marco Lucchi", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Xavier Benoit D\u2019Journo", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Paula Ugalde", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Anna Nowak", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Eric Lim", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Jacinta Wiens", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["James Huang", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Andreas Rimner", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Dorothy Giroux", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Helmut Prosch", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Wilfried Eberhardt", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Jan van Meerbeeck", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Oliver Gautschi", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Francisco Su\u00e1rez", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Yolande Lievens", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Valerie Rusch", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Fran\u00e7oise Galateau", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["David Rice", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["John Edwards", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["John J Crowley", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Enrico Ruffini", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Donald E Low", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Gail Darling", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Akif Turna", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Dean Fennell", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Seiki Hasegawa", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Andrea Bille", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Frank Detterbeck", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Jeremy Erasmus", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Fred Hirsch", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["William Travis", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Liyan Jiang", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Kwun Fong", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Jos\u00e9-Mar\u00eda Matilla", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Hedy Kindler", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Shuji Sakai", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Kemp Kernstine", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Paul Beckett", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Pier Luigi Filosso", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Thomas Rice", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Pietro Bertoglio", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["David Carbone", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Amy Stoll-D\u2019Astice", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Jim Mo Goo", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Kaoru Kubota", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Jin Mo Goo", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Hong Wei Wang", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["James Brierley", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Bill Travis", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Navneet Singh", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Meinoshin Okumura", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Andrew Nicholson", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Kazuya Kondo", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Ricardo Beyruti", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Ricardo M Terra", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Hong Kwan Kim", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Wayne Hofstetter", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["AK Cangir", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Ritu Gill", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Eugene Blackwell", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Shun-ichi Watanabe", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Luis M Montuenga", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Wentao Fang", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Katie Nishimura", 2018, "The IASLC lung cancer staging project: a renewed call to participation"], ["Heather Ritter", 2018, "A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies \u2026"], ["Karen A Gelmon", 2018, "A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies \u2026"], ["Rachel Anne Goodwin", 2018, "A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies \u2026"], ["Stephen KL Chia", 2018, "A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies \u2026"], ["Philippe L Bedard", 2018, "A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies \u2026"], ["Jonathon Torchia", 2018, "The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC)."], ["Trevor John Pugh", 2018, "The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC)."], ["Dax Torti", 2018, "The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC)."], ["Alborz Kia", 2018, "The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC)."], ["Mor Moskovitz", 2018, "The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC)."], ["Penelope Ann Bradbury", 2018, "The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC)."], ["Ramon Rami-Porta", 2018, "Staging of Thoracic Malignancies"], ["Harvey I Pass", 2018, "Staging of Thoracic Malignancies"], ["Thomas W Rice", 2018, "Staging of Thoracic Malignancies"], ["Frank C Detterbeck", 2018, "Staging of Thoracic Malignancies"], ["Deepa T Patil", 2018, "Staging of Thoracic Malignancies"], ["Betty P Poon", 2018, "833-Tyrosyl Phosphorylation of Kras Disrupts the Gtpase Cycle and Inhibits Pancreatic Cancer Cell Growth"], ["Zhong-Yin Zhang", 2018, "833-Tyrosyl Phosphorylation of Kras Disrupts the Gtpase Cycle and Inhibits Pancreatic Cancer Cell Growth"], ["for the Members of the International Association for the Study of Lung Cancer Staging and Prognostic Factors and Pathology Committees", 2018, "staging of thoracic malignancies: implications for the reporting pathologist"], ["Lillian L Siu", 2018, "Lung cancer in never smokers from the Princess Margaret Cancer Centre"], ["CA Souza", 2018, "Evidence-based best practices for EGFR T790M testing in lung cancer in Canada"], ["PK Cheema", 2018, "Evidence-based best practices for EGFR T790M testing in lung cancer in Canada"], ["B Melosky", 2018, "Evidence-based best practices for EGFR T790M testing in lung cancer in Canada"], ["A Karsan", 2018, "Evidence-based best practices for EGFR T790M testing in lung cancer in Canada"], ["T Stockley", 2018, "Evidence-based best practices for EGFR T790M testing in lung cancer in Canada"], ["A Spatz", 2018, "Evidence-based best practices for EGFR T790M testing in lung cancer in Canada"], ["V Hirsh", 2018, "Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC"], ["Q Chu", 2018, "Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC"], ["D McLeod", 2018, "Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC"], ["M-S Tsao", 2018, "Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC"], ["RA Juergens", 2018, "Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC"], ["D Ionescu", 2018, "Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC"], ["Zhenhao Fang", 2018, "Multiplexed real-time NMR GTPase assay for simultaneous monitoring of multiple guanine nucleotide exchange factor activities from human cancer cells and organoids"], ["Mari\u0301a-Jose\u0301 Sandi\u0301", 2018, "Multiplexed real-time NMR GTPase assay for simultaneous monitoring of multiple guanine nucleotide exchange factor activities from human cancer cells and organoids"], ["Robert Rottapel", 2018, "Multiplexed real-time NMR GTPase assay for simultaneous monitoring of multiple guanine nucleotide exchange factor activities from human cancer cells and organoids"], ["Tadateru Nishikawa", 2018, "Multiplexed real-time NMR GTPase assay for simultaneous monitoring of multiple guanine nucleotide exchange factor activities from human cancer cells and organoids"], ["Kenneth D Aldape", 2018, "Methylomic Profiling to Establish Tumour Clonality in Synchronous and Metachronous Non-Small Cell Lung Carcinomas"], ["Benjamin Solomon", 2018, "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American \u2026"], ["Carol Colasacco", 2018, "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American \u2026"], ["Dara L Aisner", 2018, "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American \u2026"], ["Maria E Arcila", 2018, "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American \u2026"], ["Neal I Lindeman", 2018, "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American \u2026"], ["Jan A Nowak", 2018, "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American \u2026"], ["Lesley H Souter", 2018, "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American \u2026"], ["Eric H Bernicker", 2018, "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American \u2026"], ["David J Kwiatkowski", 2018, "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American \u2026"], ["Philip T Cagle", 2018, "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American \u2026"], ["Marc Ladanyi", 2018, "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American \u2026"], ["Christina B Ventura", 2018, "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American \u2026"], ["Robyn Temple-Smolkin", 2018, "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American \u2026"], ["Ronald L Burkes", 2018, "Molecular profiling of patients with advanced colorectal Cancer: Princess Margaret Cancer Centre experience"], ["Malcolm Moore", 2018, "Molecular profiling of patients with advanced colorectal Cancer: Princess Margaret Cancer Centre experience"], ["Helen Mackay", 2018, "Molecular profiling of patients with advanced colorectal Cancer: Princess Margaret Cancer Centre experience"], ["Tong Zhang", 2018, "Molecular profiling of patients with advanced colorectal Cancer: Princess Margaret Cancer Centre experience"], ["Celeste Yu", 2018, "Molecular profiling of patients with advanced colorectal Cancer: Princess Margaret Cancer Centre experience"], ["Michael H Roehrl", 2018, "Molecular profiling of patients with advanced colorectal Cancer: Princess Margaret Cancer Centre experience"], ["Christine Brezden-Masley", 2018, "Molecular profiling of patients with advanced colorectal Cancer: Princess Margaret Cancer Centre experience"], ["Monika K Krzyzanowska", 2018, "Molecular profiling of patients with advanced colorectal Cancer: Princess Margaret Cancer Centre experience"], ["Stefano Serra", 2018, "Molecular profiling of patients with advanced colorectal Cancer: Princess Margaret Cancer Centre experience"], ["Jennifer J Knox", 2018, "Molecular profiling of patients with advanced colorectal Cancer: Princess Margaret Cancer Centre experience"], ["Joanne W Chiu", 2018, "Molecular profiling of patients with advanced colorectal Cancer: Princess Margaret Cancer Centre experience"], ["Kirtee Raparia", 2018, "Immunohistochemistry of pulmonary biomarkers: a perspective from members of the Pulmonary Pathology Society"], ["Izidor Kern", 2018, "Immunohistochemistry of pulmonary biomarkers: a perspective from members of the Pulmonary Pathology Society"], ["Natasha Rekhtman", 2018, "Immunohistochemistry of pulmonary biomarkers: a perspective from members of the Pulmonary Pathology Society"], ["Teodora Radonic", 2018, "Immunohistochemistry of pulmonary biomarkers: a perspective from members of the Pulmonary Pathology Society"], ["Lynette M Sholl", 2018, "Immunohistochemistry of pulmonary biomarkers: a perspective from members of the Pulmonary Pathology Society"], ["Lida P Hariri", 2018, "Immunohistochemistry of pulmonary biomarkers: a perspective from members of the Pulmonary Pathology Society"], ["Frank Schneider", 2018, "Immunohistochemistry of pulmonary biomarkers: a perspective from members of the Pulmonary Pathology Society"], ["Timothy Craig Allen", 2018, "Immunohistochemistry of pulmonary biomarkers: a perspective from members of the Pulmonary Pathology Society"], ["Ross Miller", 2018, "Immunohistochemistry of pulmonary biomarkers: a perspective from members of the Pulmonary Pathology Society"], ["Julien Adam", 2018, "Immunohistochemistry of pulmonary biomarkers: a perspective from members of the Pulmonary Pathology Society"], ["Marina Vivero", 2018, "Immunohistochemistry of pulmonary biomarkers: a perspective from members of the Pulmonary Pathology Society"], ["Prudence Russell", 2018, "Immunohistochemistry of pulmonary biomarkers: a perspective from members of the Pulmonary Pathology Society"], ["Vera Luiza Capelozzi", 2018, "Immunohistochemistry of pulmonary biomarkers: a perspective from members of the Pulmonary Pathology Society"], ["Igor Jurisica", 2018, "Differentially expressed microRNAs in lung adenocarcinoma invert effects of copy number aberrations of prognostic genes"], ["Wan L Lam", 2018, "Differentially expressed microRNAs in lung adenocarcinoma invert effects of copy number aberrations of prognostic genes"], ["Varune R Ramnarine", 2018, "Differentially expressed microRNAs in lung adenocarcinoma invert effects of copy number aberrations of prognostic genes"], ["Chiara Pastrello", 2018, "Differentially expressed microRNAs in lung adenocarcinoma invert effects of copy number aberrations of prognostic genes"], ["Tomas Tokar", 2018, "Differentially expressed microRNAs in lung adenocarcinoma invert effects of copy number aberrations of prognostic genes"], ["Larrisa A Pikor", 2018, "Differentially expressed microRNAs in lung adenocarcinoma invert effects of copy number aberrations of prognostic genes"], ["Emily A Vucic", 2018, "Differentially expressed microRNAs in lung adenocarcinoma invert effects of copy number aberrations of prognostic genes"], ["Simon Vary", 2018, "Differentially expressed microRNAs in lung adenocarcinoma invert effects of copy number aberrations of prognostic genes"], ["P Cheema", 2018, "Standardizing biomarker testing for Canadian patients with advanced lung cancer"], ["P Wheatley-Price", 2018, "Standardizing biomarker testing for Canadian patients with advanced lung cancer"], ["C Couture", 2018, "Standardizing biomarker testing for Canadian patients with advanced lung cancer"], ["Z Xu", 2018, "Standardizing biomarker testing for Canadian patients with advanced lung cancer"], ["N Blais", 2018, "Standardizing biomarker testing for Canadian patients with advanced lung cancer"], ["R Juergens", 2018, "Standardizing biomarker testing for Canadian patients with advanced lung cancer"], ["Francesca Lucibello", 2018, "Immunotherapy: a new standard of care in thoracic malignancies?: A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly"], ["Hasna Bouchaab", 2018, "Immunotherapy: a new standard of care in thoracic malignancies?: A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly"], ["Joachim GJV Aerts", 2018, "Immunotherapy: a new standard of care in thoracic malignancies?: A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly"], ["Franck Pag\u00e8s", 2018, "Immunotherapy: a new standard of care in thoracic malignancies?: A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly"], ["Michele Mondini", 2018, "Immunotherapy: a new standard of care in thoracic malignancies?: A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly"], ["Marina Garassino", 2018, "Immunotherapy: a new standard of care in thoracic malignancies?: A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly"], ["Thierry Berghmans", 2018, "Immunotherapy: a new standard of care in thoracic malignancies?: A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly"], ["Jacques Cadranel", 2018, "Immunotherapy: a new standard of care in thoracic malignancies?: A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly"], ["Jorge Mois\u00e9s", 2018, "Immunotherapy: a new standard of care in thoracic malignancies?: A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly"], ["Marta Grynovska", 2018, "Immunotherapy: a new standard of care in thoracic malignancies?: A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly"], ["Anne-Pascale Meert", 2018, "Immunotherapy: a new standard of care in thoracic malignancies?: A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly"], ["Julien Mazi\u00e8res", 2018, "Immunotherapy: a new standard of care in thoracic malignancies?: A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly"], ["Adrien Costantini", 2018, "Immunotherapy: a new standard of care in thoracic malignancies?: A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly"], ["Teh Ying Chou", 2018, "Interobserver variation among pathologists and refinement of criteria in distinguishing separate primary tumors from intrapulmonary metastases in lung"], ["Arne Warth", 2018, "Interobserver variation among pathologists and refinement of criteria in distinguishing separate primary tumors from intrapulmonary metastases in lung"], ["Kim Geisinger", 2018, "Interobserver variation among pathologists and refinement of criteria in distinguishing separate primary tumors from intrapulmonary metastases in lung"], ["Patrizia Viola", 2018, "Interobserver variation among pathologists and refinement of criteria in distinguishing separate primary tumors from intrapulmonary metastases in lung"], ["Kathleen Torkko", 2018, "Interobserver variation among pathologists and refinement of criteria in distinguishing separate primary tumors from intrapulmonary metastases in lung"], ["Wilbur A Franklin", 2018, "Interobserver variation among pathologists and refinement of criteria in distinguishing separate primary tumors from intrapulmonary metastases in lung"], ["Alberto Marchevsky", 2018, "Interobserver variation among pathologists and refinement of criteria in distinguishing separate primary tumors from intrapulmonary metastases in lung"], ["Ignacio I Wistuba", 2018, "Interobserver variation among pathologists and refinement of criteria in distinguishing separate primary tumors from intrapulmonary metastases in lung"], ["Edwina Duhig", 2018, "Interobserver variation among pathologists and refinement of criteria in distinguishing separate primary tumors from intrapulmonary metastases in lung"], ["Elena Pasko", 2018, "Non-driver somatic alteration burden confers good prognosis in non-small cell lung cancer"], ["Timothy M Freeman", 2018, "Non-driver somatic alteration burden confers good prognosis in non-small cell lung cancer"], ["Jiefei Tong", 2018, "Non-driver somatic alteration burden confers good prognosis in non-small cell lung cancer"], ["Jonathan Chang", 2018, "Non-driver somatic alteration burden confers good prognosis in non-small cell lung cancer"], ["Roya Navab", 2018, "Non-driver somatic alteration burden confers good prognosis in non-small cell lung cancer"], ["Dennis Wang", 2018, "Non-driver somatic alteration burden confers good prognosis in non-small cell lung cancer"], ["Filippo De Marinis", 2018, "Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study"], ["Hiroshi Isobe", 2018, "Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study"], ["Amparo Valladares", 2018, "Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study"], ["Smita Kothari", 2018, "Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study"], ["Ashwini Arunachalam", 2018, "Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study"], ["Karl-Otto Kambartel", 2018, "Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study"], ["Xiting Cao", 2018, "Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study"], ["Javier De Castro", 2018, "Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study"], ["Carlos H Barrios", 2018, "Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study"], ["Dae Ho Lee", 2018, "Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study"], ["Adnan Khattak", 2018, "Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study"], ["Thomas Burke", 2018, "Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study"], ["Ming-Shyan Huang", 2018, "Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study"], ["Celine Mascaux", 2018, "Molecular Testing in Lung Cancer"], ["F Penault-Llorca", 2017, "Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non\u2013Small-Cell Lung Cancer"], ["Parneet K Cheema", 2017, "A case of invasive mucinous pulmonary adenocarcinoma with a CD74-NRG1 fusion protein targeted with afatinib"], ["Mark Doherty", 2017, "A case of invasive mucinous pulmonary adenocarcinoma with a CD74-NRG1 fusion protein targeted with afatinib"], ["Manfred Dietel", 2017, "Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non\u2013small-cell lung cancer"], ["Reinhard B\u00fcttner", 2017, "Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non\u2013small-cell lung cancer"], ["John W Longshore", 2017, "Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non\u2013small-cell lung cancer"], ["Giuseppe Viale", 2017, "Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non\u2013small-cell lung cancer"], ["Fernando L\u00f3pez-R\u00edos", 2017, "Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non\u2013small-cell lung cancer"], ["John R Gosney", 2017, "Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non\u2013small-cell lung cancer"], ["Kenneth J Bloom", 2017, "Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non\u2013small-cell lung cancer"], ["Andrew C Wotherspoon", 2017, "Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non\u2013small-cell lung cancer"], ["Birgit Guldhammer Skov", 2017, "Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non\u2013small-cell lung cancer"], ["Fr\u00e9d\u00e9rique Penault-Llorca", 2017, "Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non\u2013small-cell lung cancer"], ["Catalin Mihalcioiu", 2017, "A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 \u2026"], ["Stephen K Chia", 2017, "A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 \u2026"], ["Wilson H Miller", 2017, "A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 \u2026"], ["Susan L Ellard", 2017, "A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 \u2026"], ["Elizabeth Eisenhauer", 2017, "A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 \u2026"], ["Vikaash Kumar", 2017, "A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 \u2026"], ["Linda Hagerman", 2017, "A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 \u2026"], ["Mihaela Mates", 2017, "A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 \u2026"], ["Sara Taylor", 2017, "A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 \u2026"], ["Caroline Lohrisch", 2017, "A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 \u2026"], ["Kwok-Kin Wong", 2017, "Synergy of WEE1 and mTOR inhibition in mutant KRAS-driven lung cancers"], ["Khanh Do", 2017, "Synergy of WEE1 and mTOR inhibition in mutant KRAS-driven lung cancers"], ["Ting Chen", 2017, "Synergy of WEE1 and mTOR inhibition in mutant KRAS-driven lung cancers"], ["Shuai Li", 2017, "Synergy of WEE1 and mTOR inhibition in mutant KRAS-driven lung cancers"], ["Lauren Bufe", 2017, "Synergy of WEE1 and mTOR inhibition in mutant KRAS-driven lung cancers"], ["Josephine Hai", 2017, "Synergy of WEE1 and mTOR inhibition in mutant KRAS-driven lung cancers"], ["Xiaoen Wang", 2017, "Synergy of WEE1 and mTOR inhibition in mutant KRAS-driven lung cancers"], ["Geoffrey I Shapiro", 2017, "Synergy of WEE1 and mTOR inhibition in mutant KRAS-driven lung cancers"], ["Shengwu Liu", 2017, "Synergy of WEE1 and mTOR inhibition in mutant KRAS-driven lung cancers"], ["C Ng", 2017, "Organoid Cultures of Lung Squamous Cell Carcinoma for Drug Screening: P3. 03-008"], ["R Quevedo", 2017, "Organoid Cultures of Lung Squamous Cell Carcinoma for Drug Screening: P3. 03-008"], ["V Stambolic", 2017, "Organoid Cultures of Lung Squamous Cell Carcinoma for Drug Screening: P3. 03-008"], ["M Pintille", 2017, "Organoid Cultures of Lung Squamous Cell Carcinoma for Drug Screening: P3. 03-008"], ["R Yuan", 2017, "MA 14.11 Malignancy Risk Prediction of Pulmonary Nodule in Lung Cancer Screening\u2013Diameter Or Volumetric Measurement"], ["JM Seely", 2017, "MA 14.11 Malignancy Risk Prediction of Pulmonary Nodule in Lung Cancer Screening\u2013Diameter Or Volumetric Measurement"], ["JR Mayo", 2017, "MA 14.11 Malignancy Risk Prediction of Pulmonary Nodule in Lung Cancer Screening\u2013Diameter Or Volumetric Measurement"], ["B Dougherty", 2017, "MA 14.11 Malignancy Risk Prediction of Pulmonary Nodule in Lung Cancer Screening\u2013Diameter Or Volumetric Measurement"], ["C Sanghera", 2017, "MA 14.11 Malignancy Risk Prediction of Pulmonary Nodule in Lung Cancer Screening\u2013Diameter Or Volumetric Measurement"], ["S Pasian", 2017, "MA 14.11 Malignancy Risk Prediction of Pulmonary Nodule in Lung Cancer Screening\u2013Diameter Or Volumetric Measurement"], ["B Van Ginneken", 2017, "MA 14.11 Malignancy Risk Prediction of Pulmonary Nodule in Lung Cancer Screening\u2013Diameter Or Volumetric Measurement"], ["D Manos", 2017, "MA 14.11 Malignancy Risk Prediction of Pulmonary Nodule in Lung Cancer Screening\u2013Diameter Or Volumetric Measurement"], ["M Tammem\u00e4gi", 2017, "MA 14.11 Malignancy Risk Prediction of Pulmonary Nodule in Lung Cancer Screening\u2013Diameter Or Volumetric Measurement"], ["R Myers", 2017, "MA 14.11 Malignancy Risk Prediction of Pulmonary Nodule in Lung Cancer Screening\u2013Diameter Or Volumetric Measurement"], ["A Ritchie", 2017, "MA 14.11 Malignancy Risk Prediction of Pulmonary Nodule in Lung Cancer Screening\u2013Diameter Or Volumetric Measurement"], ["P Burrowes", 2017, "MA 14.11 Malignancy Risk Prediction of Pulmonary Nodule in Lung Cancer Screening\u2013Diameter Or Volumetric Measurement"], ["S Tsai", 2017, "MA 14.11 Malignancy Risk Prediction of Pulmonary Nodule in Lung Cancer Screening\u2013Diameter Or Volumetric Measurement"], ["L Stewart", 2017, "MA 14.11 Malignancy Risk Prediction of Pulmonary Nodule in Lung Cancer Screening\u2013Diameter Or Volumetric Measurement"], ["C Jacobs", 2017, "MA 14.11 Malignancy Risk Prediction of Pulmonary Nodule in Lung Cancer Screening\u2013Diameter Or Volumetric Measurement"], ["M Gingras", 2017, "MA 14.11 Malignancy Risk Prediction of Pulmonary Nodule in Lung Cancer Screening\u2013Diameter Or Volumetric Measurement"], ["A Mcwilliams", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["R Finley", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["H Sekhon", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["S Cressman", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["E Haider", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["C Boylan", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["K Amjadi", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["W Evans", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["S Urbanski", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["W Tan", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["J Cutz", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["P Maceachern", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["Nasute Fauerbach", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["J English", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["D Sin", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["J Yee", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["F Laberge", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["K Soghrati", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["S Peacock", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["J Mayo", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["D Hwang", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["J Seely", 2017, "Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study: OA 15.01"], ["M Iqbal", 2017, "The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumor DNA T790M Testing: P3. 01-062"], ["I Carvalhana", 2017, "The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumor DNA T790M Testing: P3. 01-062"], ["R Burkes", 2017, "The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumor DNA T790M Testing: P3. 01-062"], ["J Rothenstein", 2017, "The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumor DNA T790M Testing: P3. 01-062"], ["D Laurence", 2017, "The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumor DNA T790M Testing: P3. 01-062"], ["T Barnes", 2017, "The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumor DNA T790M Testing: P3. 01-062"], ["N Perera-Low", 2017, "The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumor DNA T790M Testing: P3. 01-062"], ["L Wong", 2017, "The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumor DNA T790M Testing: P3. 01-062"], ["S Owen", 2017, "The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumor DNA T790M Testing: P3. 01-062"], ["J Laskin", 2017, "The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumor DNA T790M Testing: P3. 01-062"], ["L Markin", 2017, "The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumor DNA T790M Testing: P3. 01-062"], ["H Roberts", 2017, "Chronic Obstructive Pulmonary Disease Prevalence in a Lung Cancer Screening Population: MA 20.11"], ["FR Hirsch", 2017, "PL 03.03 Blueprint 2: PD-L1 immunohistochemistry comparability study in real-life, clinical samples"], ["L Kempen", 2017, "P3. 01-019 Canadian Multicenter Validation Study of Plasma Circulating Tumor DNA for Epidermal Growth Factor (EGFR) T790M Testing"], ["I Izevbaye", 2017, "P3. 01-019 Canadian Multicenter Validation Study of Plasma Circulating Tumor DNA for Epidermal Growth Factor (EGFR) T790M Testing"], ["RJ Finley", 2017, "OA 15.01 Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study"], ["PV Nasute Fauerbach", 2017, "OA 15.01 Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study"], ["WC Tan", 2017, "OA 15.01 Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study"], ["HS Sekhon", 2017, "OA 15.01 Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study"], ["SJ Peacock", 2017, "OA 15.01 Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study"], ["JC English", 2017, "OA 15.01 Lung Cancer Screening: Participant Selection by Risk Model\u2013the Pan-Canadian Study"], ["M Chui", 2017, "MA 13.02 Comprehensive Genetic Analysis Related to PD-L1 Expression in Early-stage Lung Squamous Cell Carcinoma"], ["K Brovsky", 2017, "MA 13.02 Comprehensive Genetic Analysis Related to PD-L1 Expression in Early-stage Lung Squamous Cell Carcinoma"], ["C Genova", 2017, "MA 13.02 Comprehensive Genetic Analysis Related to PD-L1 Expression in Early-stage Lung Squamous Cell Carcinoma"], ["T Sporn", 2017, "MA 13.02 Comprehensive Genetic Analysis Related to PD-L1 Expression in Early-stage Lung Squamous Cell Carcinoma"], ["DR Gandara", 2017, "MA 13.02 Comprehensive Genetic Analysis Related to PD-L1 Expression in Early-stage Lung Squamous Cell Carcinoma"], ["Colm Boylan", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["John Yee", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["PanCan Study Team", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Serge Puksa", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Wan C Tan", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Francis Laberge", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Kayvan Amjadi", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["John C English", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Harmanjatinder S Sekhon", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Michael R Johnston", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Don D Sin", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Kam Soghrati", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Richard J Finley", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Glenwood D Goss", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Annette McWilliams", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Sonya Cressman", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Stuart J Peacock", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["William K Evans", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Ehsan Haider", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Paul MacEachern", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Stefan Urbanski", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Jean-Claude Cutz", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Paola V Nasute Fauerbach", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Kazuhiro Yasufuku", 2017, "Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study"], ["Irene Brana", 2017, "Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts"], ["Blaise A Clarke", 2017, "Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts"], ["Lucia Kim", 2017, "Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts"], ["Yuhui Wang", 2017, "Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts"], ["Rafael Sierra", 2017, "Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts"], ["Peter Loparco", 2017, "Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts"], ["Benjamin G Neel", 2017, "Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts"], ["Bo Ram Kim", 2017, "Identification of the SOX2 interactome by BioID reveals EP300 as a mediator of SOX2-dependent squamous differentiation and lung squamous cell carcinoma growth"], ["Estelle MN Laurent", 2017, "Identification of the SOX2 interactome by BioID reveals EP300 as a mediator of SOX2-dependent squamous differentiation and lung squamous cell carcinoma growth"], ["Etienne Coyaud", 2017, "Identification of the SOX2 interactome by BioID reveals EP300 as a mediator of SOX2-dependent squamous differentiation and lung squamous cell carcinoma growth"], ["Emily Van de Laar", 2017, "Identification of the SOX2 interactome by BioID reveals EP300 as a mediator of SOX2-dependent squamous differentiation and lung squamous cell carcinoma growth"], ["Brian Raught", 2017, "Identification of the SOX2 interactome by BioID reveals EP300 as a mediator of SOX2-dependent squamous differentiation and lung squamous cell carcinoma growth"], ["Jonathan St-Germain", 2017, "Identification of the SOX2 interactome by BioID reveals EP300 as a mediator of SOX2-dependent squamous differentiation and lung squamous cell carcinoma growth"], ["Nevin Murray", 2017, "A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND. 196"], ["Jean Powers", 2017, "A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND. 196"], ["Cheryl Ho", 2017, "A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND. 196"], ["Glenwood Goss", 2017, "A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND. 196"], ["Zhuo Chen", 2017, "A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND. 196"], ["TJ Pugh", 2017, "127PEGFR copy number aberrations detected in cfDNA from advanced NSCLC patients"], ["GM O'Kane", 2017, "127PEGFR copy number aberrations detected in cfDNA from advanced NSCLC patients"], ["NB Leighl", 2017, "127PEGFR copy number aberrations detected in cfDNA from advanced NSCLC patients"], ["Mark K Doherty", 2017, "Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)"], ["Rick Wang", 2017, "Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)"], ["Bethany Pitcher", 2017, "Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)"], ["Marco Angelo Burgio", 2017, "Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients"], ["Alessandro Morabito", 2017, "Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients"], ["Antonio Rossi", 2017, "Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients"], ["Cesare Gridelli", 2017, "Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients"], ["Massimo Di Maio", 2017, "Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients"], ["Ciro Gallo", 2017, "Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients"], ["Fortunato Ciardiello", 2017, "Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients"], ["Paolo Maione", 2017, "Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients"], ["Dengxiao Cheng", 2017, "Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients"], ["Vittorio Gebbia", 2017, "Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients"], ["Mauro Saieg", 2017, "Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients"], ["Simona Signoriello", 2017, "Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients"], ["Francesco Perrone", 2017, "Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients"], ["Yasmin Alam", 2017, "Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients"], ["Charles Butts", 2017, "Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients"], ["Emily McPherson", 2017, "The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency"], ["Reka Pataky", 2017, "The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency"], ["Diana N Ionescu", 2017, "The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency"], ["Martin C Tammem\u00e4gi", 2017, "The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency"], ["Hirokazu Watanabe", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["M N\u00fa\u00f1ez Delgado", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["R Melchor \u00cd\u00f1iguez", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["B de Olaiz Navarro", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["S Kostas", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["J S\u00e1nchez de Cos Escu\u00edn", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["E Fern\u00e1ndez Araujo", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["H Hern\u00e1ndez Rodr\u00edguez", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["D Ball", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["MJ Pav\u00f3n Fern\u00e1ndez", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["M Rosenberg", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["C \u00c1lvarez de Arriba", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["L De Esteban J\u00falvez", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["AI Blanco Orozco", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["L Miravet Sorribes", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["D Subotic", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Antoon Lerut", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["I Escobar Campuzano", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["JA Gull\u00f3n Blanco", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["R Guijarro Jorge", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Kenji Suzuki", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Jean-Paul Sculier", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Kelly Stratton", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Haruhiko Kondo", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["J Hern\u00e1ndez Hern\u00e1ndez", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Patti Groome", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["G Francisco Corral", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["E Jakobsen", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["M Serra Mitjans", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Jhingook Kim", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["A Arnau Obrer", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["I Mac\u00eda Vidueira", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Nagahiro Saijo", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Charles F Thomas Jr", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["I Parente Lamelas", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["M Liao", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Fergus Gleeson", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Laura Kingsbury", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Andrew Turrisi", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["MG Blum", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Peter Goldstraw", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["A Saura Vinuesa", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Eric Valli\u00e8res", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["G Gonz\u00e1lez Casaurr\u00e1n", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["M Mari\u00f1\u00e1n Gorospe", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["S Swisher", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["S Naranjo Gozalo", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["K Tournoy", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Kenneth Rosenzweig", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Yuji Tachimori", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["P Van Schil", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["C Kennedy", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["M Iglesias Heras", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Kouki Inai", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["V Cvijanovic", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["TE Strand", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["JM Izquierdo Elena", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Alan Mitchell", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["R Magaroles", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["MA Gonz\u00e1lez Castro", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["S Garc\u00eda Barajas", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["B McCaughan", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Yi-Long Wu", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Wilfried Ernst Erich Eberhardt", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Mark Krasnik", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["A N\u00fa\u00f1ez Ares", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["David G Beer", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Lee Krug", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["F Abad Cavaco", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["J Abal Arca", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["F Andreo Garc\u00eda", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["JC Pe\u00f1alver Cuesta", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["H Pass", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["MT Gonz\u00e1lez Budi\u00f1o", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Kristiaan Nackaerts", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Takashi Nakano", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["JS Park", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["C Thomas", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["M Losanovscky", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Michael Peake", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["P Le\u00f3n Atance", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["M Velasquez", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["J Herrero Collantes", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Edith M Marom", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["E Ans\u00f3tegui Barrera", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["S Cerezo Gonz\u00e1lez", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["KM Fong", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["J Freixinet Gilart", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["R Terra", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Catherine Kennedy", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["D Chimondeguy", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["P Girard", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["E Ruffini", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Eugene Blackstone", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["J Padilla Alarc\u00f3n", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["David Ball", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["T Goksel", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["K Yokoi", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["S Defranchi", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["G Lyons", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["L Garc\u00eda Arang\u00fcena", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["YL Wu", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["GK Bascom", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Conrad Falkson", 2017, "The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer"], ["Jonathan Beesley", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Jennifer A Doherty", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Henricus FM van der Heijden", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["SpiroMeta Consortium", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Margaret R Spitz", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["James D McKay", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Karen A Pooley", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Nathan C Gaddis", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Neil E Caporaso", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Alison Dunning", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Lynne R Wilkens", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Gunnar W Reginsson", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Eric O Johnson", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Claudio Pikielny", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Maria N Timofeeva", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Sara Lindstr\u00f6em", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Richard S Houlston", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Thorunn Rafnar", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Victoria L Stevens", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Linda Kachuri", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Sharon M Lutz", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Christopher A Haiman", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Thorgeir E Thorgeirsson", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Laura J Bierut", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Kari Stefansson", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Ma'en Obeidat", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Matt P Barnett", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Pier Alberto Bertazzi", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Thomas R Muley", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Dana B Hancock", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Georgia Chenevix-Trench", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Xia Jiang", 2017, "Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes"], ["Katherine-M Pisters", 2017, "Uncommon EGFR mutations in advanced non-small cell lung cancer"], ["Pasi A J\u00e4nne", 2017, "Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non\u2013small-cell lung cancer in \u2026"], ["Thierry Le Chevalier", 2017, "Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non\u2013small-cell lung cancer in \u2026"], ["Jean-Yves Douillard", 2017, "Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non\u2013small-cell lung cancer in \u2026"], ["Pierre Hainaut", 2017, "Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non\u2013small-cell lung cancer in \u2026"], ["Martin Filipits", 2017, "Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non\u2013small-cell lung cancer in \u2026"], ["Gw\u00e9na\u00ebl Le Teuff", 2017, "Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non\u2013small-cell lung cancer in \u2026"], ["Elizabeth Brambilla", 2017, "Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non\u2013small-cell lung cancer in \u2026"], ["Benjamin Lacas", 2017, "Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non\u2013small-cell lung cancer in \u2026"], ["Robert Pirker", 2017, "Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non\u2013small-cell lung cancer in \u2026"], ["Stephen Graziano", 2017, "Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non\u2013small-cell lung cancer in \u2026"], ["Janelle Ramsahai", 2017, "Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium."], ["Patricia Ann Shaw", 2017, "Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium."], ["Anna Tinker", 2017, "Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium."], ["Blaise Clarke", 2017, "Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium."], ["Swati Garg", 2017, "Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium."], ["Johanne Ingrid Weberpals", 2017, "Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium."], ["Yada Kanjanapan", 2017, "Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium."], ["Kelly Brooks", 2017, "Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium."], ["David Shao Peng Tan", 2017, "Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium."], ["Greg Jones", 2017, "Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC)."], ["Clive D Morris", 2017, "Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC)."], ["Emma Green", 2017, "Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC)."], ["Peter Michael Ellis", 2017, "Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC)."], ["Keyue Ding", 2017, "Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC)."], ["Frank De Kievit", 2017, "Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC)."], ["Mussawar Iqbal", 2017, "Patients\u2019 willingness to pay for blood-based EGFR T790M testing: Results from a Canadian validation study of circulating DNA T790M testing."], ["Leslie Markin", 2017, "Patients\u2019 willingness to pay for blood-based EGFR T790M testing: Results from a Canadian validation study of circulating DNA T790M testing."], ["Parneet Kaur Cheema", 2017, "Patients\u2019 willingness to pay for blood-based EGFR T790M testing: Results from a Canadian validation study of circulating DNA T790M testing."], ["Tristan Alexandra Barnes", 2017, "Patients\u2019 willingness to pay for blood-based EGFR T790M testing: Results from a Canadian validation study of circulating DNA T790M testing."], ["Linda Wong", 2017, "Patients\u2019 willingness to pay for blood-based EGFR T790M testing: Results from a Canadian validation study of circulating DNA T790M testing."], ["Magdalena Sawczak", 2017, "Patients\u2019 willingness to pay for blood-based EGFR T790M testing: Results from a Canadian validation study of circulating DNA T790M testing."], ["Jeffrey Rothenstein", 2017, "Patients\u2019 willingness to pay for blood-based EGFR T790M testing: Results from a Canadian validation study of circulating DNA T790M testing."], ["David Laurence", 2017, "Patients\u2019 willingness to pay for blood-based EGFR T790M testing: Results from a Canadian validation study of circulating DNA T790M testing."], ["Janessa J Laskin", 2017, "Patients\u2019 willingness to pay for blood-based EGFR T790M testing: Results from a Canadian validation study of circulating DNA T790M testing."], ["Scott Peter Owen", 2017, "Patients\u2019 willingness to pay for blood-based EGFR T790M testing: Results from a Canadian validation study of circulating DNA T790M testing."], ["Ilda Carvalhana", 2017, "Patients\u2019 willingness to pay for blood-based EGFR T790M testing: Results from a Canadian validation study of circulating DNA T790M testing."], ["Nicole Perera-Low", 2017, "Patients\u2019 willingness to pay for blood-based EGFR T790M testing: Results from a Canadian validation study of circulating DNA T790M testing."], ["Janice Rudkowski", 2017, "Use of a marketing plan for recruitment to a lung cancer screening study."], ["Garth Andrew Nicholas", 2017, "Use of a marketing plan for recruitment to a lung cancer screening study."], ["Pan-Canadian Early Detection of Lung Cancer Study Research Team", 2017, "Use of a marketing plan for recruitment to a lung cancer screening study."], ["Martin Tammemagi", 2017, "Use of a marketing plan for recruitment to a lung cancer screening study."], ["Heidi Roberts", 2017, "Use of a marketing plan for recruitment to a lung cancer screening study."], ["Stephen C Lam", 2017, "Use of a marketing plan for recruitment to a lung cancer screening study."], ["Gregory Russell Pond", 2017, "Use of a marketing plan for recruitment to a lung cancer screening study."], ["David W Cescon", 2017, "BRM Promoter Polymorphisms and Survival of Advanced Non\u2013Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR. 24 Trial"], ["David N Reisman", 2017, "BRM Promoter Polymorphisms and Survival of Advanced Non\u2013Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR. 24 Trial"], ["Xin Qiu", 2017, "BRM Promoter Polymorphisms and Survival of Advanced Non\u2013Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR. 24 Trial"], ["Sinead Cuffe", 2017, "BRM Promoter Polymorphisms and Survival of Advanced Non\u2013Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR. 24 Trial"], ["Wei Xu", 2017, "BRM Promoter Polymorphisms and Survival of Advanced Non\u2013Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR. 24 Trial"], ["C Tse Brandon", 2017, "BRM Promoter Polymorphisms and Survival of Advanced Non\u2013Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR. 24 Trial"], ["Devalben Patel", 2017, "BRM Promoter Polymorphisms and Survival of Advanced Non\u2013Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR. 24 Trial"], ["Bingshu E Chen", 2017, "BRM Promoter Polymorphisms and Survival of Advanced Non\u2013Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR. 24 Trial"], ["Abul Kalam Azad", 2017, "BRM Promoter Polymorphisms and Survival of Advanced Non\u2013Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR. 24 Trial"], ["Lu Cheng", 2017, "BRM Promoter Polymorphisms and Survival of Advanced Non\u2013Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR. 24 Trial"], ["Dangxiao Cheng", 2017, "BRM Promoter Polymorphisms and Survival of Advanced Non\u2013Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR. 24 Trial"], ["Rayjean Hung", 2017, "BRM Promoter Polymorphisms and Survival of Advanced Non\u2013Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR. 24 Trial"], ["Shermi Liang", 2017, "BRM Promoter Polymorphisms and Survival of Advanced Non\u2013Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR. 24 Trial"], ["Scott A Laurie", 2017, "BRM Promoter Polymorphisms and Survival of Advanced Non\u2013Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR. 24 Trial"], ["Jeffrey Bruce", 2017, "BRM Promoter Polymorphisms and Survival of Advanced Non\u2013Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR. 24 Trial"], ["Caroline Chung", 2017, "Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer"], ["Moein Alizadeh", 2017, "Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer"], ["Celine M Mascaux", 2017, "Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer"], ["Petra Martin", 2017, "Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer"], ["G Qing", 2017, "LBA1Establishment of a diagnostic algorithm for ROS1 testing in Canada"], ["E Torlakovic", 2017, "LBA1Establishment of a diagnostic algorithm for ROS1 testing in Canada"], ["A Smith", 2017, "LBA1Establishment of a diagnostic algorithm for ROS1 testing in Canada"], ["CC Cheung", 2017, "LBA1Establishment of a diagnostic algorithm for ROS1 testing in Canada"], ["G Bigras", 2017, "LBA1Establishment of a diagnostic algorithm for ROS1 testing in Canada"], ["H Wang", 2017, "LBA1Establishment of a diagnostic algorithm for ROS1 testing in Canada"], ["C Butts", 2017, "Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective"], ["BS Sheffield", 2017, "Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective"], ["M Sukhai", 2017, "Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective"], ["M Pakkal", 2017, "Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective"], ["R Sangha", 2017, "Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective"], ["M Patel", 2017, "Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario"], ["R El-Maraghi", 2017, "Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario"], ["T Waddell", 2017, "Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario"], ["T Chung", 2017, "Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario"], ["DM Hwang", 2017, "Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario"], ["A Brade", 2017, "Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario"], ["C Lim", 2017, "Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario"], ["M Binnie", 2017, "Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario"], ["G da Cunha Santos", 2017, "Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario"], ["N Paul", 2017, "Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario"], ["RF Carter", 2017, "Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario"], ["C Sit", 2017, "Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario"], ["JC Cutz", 2017, "Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario"], ["FA Shepherd", 2017, "PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer"], ["M Filipits", 2017, "PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer"], ["G Le Teuff", 2017, "PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer"], ["C Landais", 2017, "PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer"], ["J-C Soria", 2017, "PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer"], ["E Brambilla", 2017, "PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer"], ["R Pirker", 2017, "PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer"], ["L Seymour", 2017, "PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer"], ["S Graziano", 2017, "PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer"], ["T Le Chevalier", 2017, "PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer"], ["J-P Pignon", 2017, "PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer"], ["P Hainaut", 2017, "PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer"], ["R Kratze", 2017, "PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer"], ["Rosalyn A Juergens", 2017, "Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck"], ["Albiruni RA Razak", 2017, "Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck"], ["Scott V Bratman", 2017, "Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck"], ["M Sara Kuruvilla", 2017, "Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck"], ["Aaron R Hansen", 2017, "Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck"], ["Eunhee S Yi", 2017, "Diagnosis of acute cellular rejection and antibody-mediated rejection on lung transplant biopsies: a perspective from members of the pulmonary pathology society"], ["Roberto J Barrios", 2017, "Diagnosis of acute cellular rejection and antibody-mediated rejection on lung transplant biopsies: a perspective from members of the pulmonary pathology society"], ["Ross A Miller", 2017, "Diagnosis of acute cellular rejection and antibody-mediated rejection on lung transplant biopsies: a perspective from members of the pulmonary pathology society"], ["Maxwell L Smith", 2017, "Diagnosis of acute cellular rejection and antibody-mediated rejection on lung transplant biopsies: a perspective from members of the pulmonary pathology society"], ["Yimin Ge", 2017, "Diagnosis of acute cellular rejection and antibody-mediated rejection on lung transplant biopsies: a perspective from members of the pulmonary pathology society"], ["Mary B Beasley", 2017, "Diagnosis of acute cellular rejection and antibody-mediated rejection on lung transplant biopsies: a perspective from members of the pulmonary pathology society"], ["Vera L Capelozzi", 2017, "Diagnosis of acute cellular rejection and antibody-mediated rejection on lung transplant biopsies: a perspective from members of the pulmonary pathology society"], ["Marie Christine Aubry", 2017, "Diagnosis of acute cellular rejection and antibody-mediated rejection on lung transplant biopsies: a perspective from members of the pulmonary pathology society"], ["Anat Hershko-Klement", 2017, "ALK-rearranged non\u2013small-cell lung cancer is associated with a high rate of venous thromboembolism"], ["Elizabeth Dudnik", 2017, "ALK-rearranged non\u2013small-cell lung cancer is associated with a high rate of venous thromboembolism"], ["Mira Wollner", 2017, "ALK-rearranged non\u2013small-cell lung cancer is associated with a high rate of venous thromboembolism"], ["Tzippy Shochat", 2017, "ALK-rearranged non\u2013small-cell lung cancer is associated with a high rate of venous thromboembolism"], ["Ronald Burkes", 2017, "ALK-rearranged non\u2013small-cell lung cancer is associated with a high rate of venous thromboembolism"], ["Ludmila Fridel", 2017, "ALK-rearranged non\u2013small-cell lung cancer is associated with a high rate of venous thromboembolism"], ["Nir Peled", 2017, "ALK-rearranged non\u2013small-cell lung cancer is associated with a high rate of venous thromboembolism"], ["Erin L Stewart", 2017, "Characterizing the last holdouts"], ["Masaki Anraku", 2017, "Patient-derived xenograft establishment from human malignant pleural mesothelioma"], ["Zhihong Yun", 2017, "Patient-derived xenograft establishment from human malignant pleural mesothelioma"], ["Thomas John", 2017, "Patient-derived xenograft establishment from human malignant pleural mesothelioma"], ["Tetsuzo Tagawa", 2017, "Patient-derived xenograft establishment from human malignant pleural mesothelioma"], ["Ron Feld", 2017, "Patient-derived xenograft establishment from human malignant pleural mesothelioma"], ["Ghassan Allo", 2017, "Patient-derived xenograft establishment from human malignant pleural mesothelioma"], ["Emin Ibrahimov", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Nicholas Buchner", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Thomas J Hudson", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Julie M Wilson", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Ilinca Lungu", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Ayelet Borgida", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["AM Brown", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Ashton A Connor", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Calvin Law", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Jeremy Johns", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Dianne Chadwick", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Jared T Simpson", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Lee Timms", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Jaeseung C Kim", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Karen Ng", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["John D McPherson", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Michael A Hollingsworth", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Sheng-Ben Liang", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Danielle Pasternack", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Lawrence Heisler", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Michelle Chan-Seng-Yue", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Sara Hafezi-Bakhtiari", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Liran I Shlush", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Francisco X Real", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Yilong Li", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Gun Ho Jang", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Timothy Beck", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["John E Dick", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["George Zogopoulos", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Lincoln D Stein", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["JM Bartlett", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Sean P Cleary", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["LG Jorgensen", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Faiyaz Notta", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Mathieu Lemire", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Ludmil B Alexandrov", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Gloria M Petersen", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Robert E Denroche", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Steven Gallinger", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Gavin W Wilson", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Peter J Campbell", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Christina K Yung", 2017, "Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns."], ["Tahani Al-Bager", 2017, "Lung Transplant Outcomes in Emphysema Patients with Granulomas"], ["Yizhuo Gao", 2017, "Lung Transplant Outcomes in Emphysema Patients with Granulomas"], ["Sassan Azad", 2017, "Lung Transplant Outcomes in Emphysema Patients with Granulomas"], ["Zanobia Khan", 2017, "Lung Transplant Outcomes in Emphysema Patients with Granulomas"], ["Rex Michael Santiago", 2017, "Lung Transplant Outcomes in Emphysema Patients with Granulomas"], ["Anita Hall", 2017, "A preclinical trial to evaluate therapies for BRCA-associated pancreatic cancer."], ["David W Hedley", 2017, "A preclinical trial to evaluate therapies for BRCA-associated pancreatic cancer."], ["Jin Yong Patrick Park", 2017, "A preclinical trial to evaluate therapies for BRCA-associated pancreatic cancer."], ["Birgit Witte", 2017, "The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases"], ["Michael den Bakker", 2017, "The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases"], ["Yoshihiro Matsuno", 2017, "The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases"], ["Yuko Minami", 2017, "The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases"], ["Kelly Butnor", 2017, "The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases"], ["Erienne de Cuba", 2017, "The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases"], ["Douglas B Flieder", 2017, "The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases"], ["Seena C Aisner", 2017, "The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases"], ["Naoto Keino", 2017, "The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases"], ["Reinhard H Buettner", 2017, "The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases"], ["Akihiko Yoshida", 2017, "The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases"], ["Alberto M Marchevsky", 2017, "The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases"], ["Kim R Geisinger", 2017, "The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases"], ["Yuichi Ishikawa", 2017, "The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases"], ["John Longshore", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["Amita Mistry", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["Malinka Jansson", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["William Richardson", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["Bharathi Vennapusa", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["Abigail McElhinny", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["Ian McCaffery", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["Steve Averbuch", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["Jill Walker", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["James Ranger-Moore", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["Eric Rubin", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["J Andrew Williams", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["Debra Hanks", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["Dave Stanforth", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["Kenneth Emancipator", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["Karina Kulangara", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["Penny Towne", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["James Novotny", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["Rasika Kalamegham", 2017, "PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project"], ["Maud HW Starmans", 2017, "Molecular heterogeneity of non\u2010small cell lung carcinoma patient\u2010derived xenografts closely reflect their primary tumors"], ["Christine To", 2017, "Molecular heterogeneity of non\u2010small cell lung carcinoma patient\u2010derived xenografts closely reflect their primary tumors"], ["Vladimir Ignatchenko", 2017, "Molecular heterogeneity of non\u2010small cell lung carcinoma patient\u2010derived xenografts closely reflect their primary tumors"], ["Thomas Kislinger", 2017, "Molecular heterogeneity of non\u2010small cell lung carcinoma patient\u2010derived xenografts closely reflect their primary tumors"], ["Yuhong Wei", 2017, "Molecular heterogeneity of non\u2010small cell lung carcinoma patient\u2010derived xenografts closely reflect their primary tumors"], ["Dan Strumpf", 2017, "Molecular heterogeneity of non\u2010small cell lung carcinoma patient\u2010derived xenografts closely reflect their primary tumors"], ["Chang\u2010Qi Zhu", 2017, "Molecular heterogeneity of non\u2010small cell lung carcinoma patient\u2010derived xenografts closely reflect their primary tumors"], ["Sharon Lee", 2017, "Molecular heterogeneity of non\u2010small cell lung carcinoma patient\u2010derived xenografts closely reflect their primary tumors"], ["Lakshmi Muthuswamy", 2017, "Molecular heterogeneity of non\u2010small cell lung carcinoma patient\u2010derived xenografts closely reflect their primary tumors"], ["Michelle A Chan\u2010Seng\u2010Yue", 2017, "Molecular heterogeneity of non\u2010small cell lung carcinoma patient\u2010derived xenografts closely reflect their primary tumors"], ["Lei Li", 2017, "Molecular heterogeneity of non\u2010small cell lung carcinoma patient\u2010derived xenografts closely reflect their primary tumors"], ["Naoki Yanagawa", 2017, "Molecular heterogeneity of non\u2010small cell lung carcinoma patient\u2010derived xenografts closely reflect their primary tumors"], ["Quang M Trinh", 2017, "Molecular heterogeneity of non\u2010small cell lung carcinoma patient\u2010derived xenografts closely reflect their primary tumors"], ["Paul Taylor", 2017, "Molecular heterogeneity of non\u2010small cell lung carcinoma patient\u2010derived xenografts closely reflect their primary tumors"], ["Nhu\u2010An Pham", 2017, "Molecular heterogeneity of non\u2010small cell lung carcinoma patient\u2010derived xenografts closely reflect their primary tumors"], ["Shawna L Organ", 2017, "TRIM14 is a putative tumor suppressor and regulator of innate immune response in non-small cell lung cancer"], ["Lecia V Sequist", 2017, "Tackling the Next Generation of Resistance in EGFR-Mutant"], ["Zofia Piotrowska", 2017, "Tackling the Next Generation of Resistance in EGFR-Mutant"], ["CJ Shiau", 2017, "Molecular Testing in Lung Cancer"], ["James D Mckay", 2017, "Pleiotropy of genetic variants on obesity and smoking phenotypes: Results from the Oncoarray Project of The International Lung Cancer Consortium"], ["Gloria YF Ho", 2017, "Pleiotropy of genetic variants on obesity and smoking phenotypes: Results from the Oncoarray Project of The International Lung Cancer Consortium"], ["Yiqun Wu", 2017, "Pleiotropy of genetic variants on obesity and smoking phenotypes: Results from the Oncoarray Project of The International Lung Cancer Consortium"], ["Jee-Young Moon", 2017, "Pleiotropy of genetic variants on obesity and smoking phenotypes: Results from the Oncoarray Project of The International Lung Cancer Consortium"], ["Donald Gullberg", 2017, "Role of the Extracellular Matrix in Tumor Stroma: Barrier or Support?"], ["Marion Kusche-Gullberg", 2017, "Role of the Extracellular Matrix in Tumor Stroma: Barrier or Support?"], ["C\u00e9dric Zeltz", 2017, "Role of the Extracellular Matrix in Tumor Stroma: Barrier or Support?"], ["Grzegorz Korpanty", 2017, "OA21. 02 ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism"], ["Richard M Martin", 2017, "Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study"], ["George Davey Smith", 2017, "Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study"], ["Erik HFM Van Der Heijden", 2017, "Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study"], ["W Jay Christian", 2017, "Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study"], ["Mikael B Johansson", 2017, "Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study"], ["Philip C Haycock", 2017, "Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study"], ["Kaitlin H Wade", 2017, "Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study"], ["Milan Savi\u0107", 2017, "Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study"], ["Dana Mates", 2017, "Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study"], ["Demetrius Albanes", 2017, "Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study"], ["Sungshim L Park", 2017, "Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study"], ["Caroline L Relton", 2017, "Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study"], ["Lo\u00efc Le Marchand", 2017, "Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study"], ["Peter Kraft", 2017, "Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study"], ["SANJA Dacic", 2017, "IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer"], ["YASUSHI Yatabe", 2017, "IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer"], ["KEITH M Kerr", 2017, "IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer"], ["MING SOUND Tsao", 2017, "IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer"], ["Claudia Polari", 2017, "PUB015 The Use of Immunohistochemistry Improves the Diagnosis of SCLC. An International Reproducibility Study in a Demanding Set of Cases"], ["Erienne De Cuba", 2017, "PUB015 The Use of Immunohistochemistry Improves the Diagnosis of SCLC. An International Reproducibility Study in a Demanding Set of Cases"], ["Michael Den Bakker", 2017, "PUB015 The Use of Immunohistochemistry Improves the Diagnosis of SCLC. An International Reproducibility Study in a Demanding Set of Cases"], ["Reinhard Buettner", 2017, "PUB015 The Use of Immunohistochemistry Improves the Diagnosis of SCLC. An International Reproducibility Study in a Demanding Set of Cases"], ["Douglas Flieder", 2017, "PUB015 The Use of Immunohistochemistry Improves the Diagnosis of SCLC. An International Reproducibility Study in a Demanding Set of Cases"], ["Alain Borczuk", 2017, "PUB015 The Use of Immunohistochemistry Improves the Diagnosis of SCLC. An International Reproducibility Study in a Demanding Set of Cases"], ["Wilbur Franklin", 2017, "P3. 01-021 Reproducibility of Comprehensive Histologic Assessment and Refining Histologic Criteria in P Staging of Multiple Tumor Nodules: Topic: Morphology"], ["Shirley Tam", 2017, "MA17. 06 Landscape of Somatic Mutations Involving Lung Cancer Associated Genes in Non-Small Cell Lung Cancer (NSCLC) Patient-Derived Xenografts"], ["Trevor Pugh", 2017, "P3. 02b-028 Characterizing Residual Erlotinib-Tolerant Population Using EGFR-Mutated NSCLC Primary Derived Xenografts: The Last Holdouts: Topic: EGFR Biomarkers"], ["Daniel De Carvalho", 2017, "P3. 02b-028 Characterizing Residual Erlotinib-Tolerant Population Using EGFR-Mutated NSCLC Primary Derived Xenografts: The Last Holdouts: Topic: EGFR Biomarkers"], ["Erin Stewart", 2017, "P3. 02b-028 Characterizing Residual Erlotinib-Tolerant Population Using EGFR-Mutated NSCLC Primary Derived Xenografts: The Last Holdouts: Topic: EGFR Biomarkers"], ["Tiantian Li", 2017, "P3. 02b-028 Characterizing Residual Erlotinib-Tolerant Population Using EGFR-Mutated NSCLC Primary Derived Xenografts: The Last Holdouts: Topic: EGFR Biomarkers"], ["Jeff Bruce", 2017, "P3. 02b-028 Characterizing Residual Erlotinib-Tolerant Population Using EGFR-Mutated NSCLC Primary Derived Xenografts: The Last Holdouts: Topic: EGFR Biomarkers"], ["Shu Yi Shen", 2017, "P3. 02b-028 Characterizing Residual Erlotinib-Tolerant Population Using EGFR-Mutated NSCLC Primary Derived Xenografts: The Last Holdouts: Topic: EGFR Biomarkers"], ["Mamatjan Yasin", 2017, "P2. 03b-089 CD1C in Lung Adenocarcinoma: Prognosis and Cellular Origin: Topic: Biomarkers"], ["Dipikaa Akshinthala", 2017, "P2. 03b-070 Establishment of Organoid Cell Lines from Lung Squamous Cell Carcinoma: Topic: Biomarkers"], ["Ethan Kaufman", 2017, "P1. 05-006 Identification of miRNAs and mRNAs Associated with Metastasis in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Topic: Translational Research and Biomarkers"], ["Ashley Kowalewski", 2017, "OA19. 01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium"], ["David R Gandara", 2017, "OA19. 01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium"], ["Mark Watson", 2017, "OA19. 01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium"], ["Zhengming Chen", 2017, "OA19. 01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium"], ["Ramaswamy Govindan", 2017, "OA19. 01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium"], ["Thomas Sporn", 2017, "OA19. 01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium"], ["David Harpole", 2017, "OA19. 01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium"], ["Mary-Beth Joshi", 2017, "OA19. 01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium"], ["Christopher Rivard", 2017, "OA19. 01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium"], ["Adriaan Van Bokhoven", 2017, "OA19. 01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium"], ["Frances Shepard", 2017, "OA19. 01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium"], ["Mark Onaitis", 2017, "OA19. 01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium"], ["Karla Ballman", 2017, "OA19. 01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium"], ["Daniel Merrick", 2017, "OA19. 01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium"], ["Guoan Chen", 2017, "OA19. 01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium"], ["Carlo Genova", 2017, "OA19. 01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium"], ["Herman Chui", 2017, "OA19. 01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium"], ["William Richards", 2017, "OA19. 01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium"], ["Venkata Satya Kumar Manem", 2017, "P3. 01-019 Desmoplasia is Associated with Poor Prognosis and Carcinoma-Associated Fibroblast Heterogeneity in Non-Small Cell Lung Cancer: Topic: Morphology"], ["Michael Moran", 2017, "PUB052 Proteome Signatures and New Cancer Drivers"], ["Wen Zhang", 2017, "PUB052 Proteome Signatures and New Cancer Drivers"], ["Frances Allison", 2017, "P2. 03b-077 EGFR/ALK+ Patient-Derived Xenografts from Advanced NSCLC for TKI Drug Selection & Resistance Development: The REAL-PDX Study: Topic: Biomarkers"], ["Alexandria Grindlay", 2017, "P2. 03b-077 EGFR/ALK+ Patient-Derived Xenografts from Advanced NSCLC for TKI Drug Selection & Resistance Development: The REAL-PDX Study: Topic: Biomarkers"], ["Judy Mcconnell", 2017, "P2. 03b-077 EGFR/ALK+ Patient-Derived Xenografts from Advanced NSCLC for TKI Drug Selection & Resistance Development: The REAL-PDX Study: Topic: Biomarkers"], ["Jing Xu", 2017, "Senescent carcinoma-associated fibroblasts upregulate IL8 to enhance prometastatic phenotypes"], ["Kit Man Wong", 2017, "A Cost-Effectiveness Analysis of Using the JBR. 10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non\u2013Small-Cell Lung Cancer"], ["Raymond Ng", 2017, "A Cost-Effectiveness Analysis of Using the JBR. 10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non\u2013Small-Cell Lung Cancer"], ["Sandy D Der", 2017, "A Cost-Effectiveness Analysis of Using the JBR. 10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non\u2013Small-Cell Lung Cancer"], ["Carmen Chung", 2017, "A Cost-Effectiveness Analysis of Using the JBR. 10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non\u2013Small-Cell Lung Cancer"], ["Suzanne Li", 2017, "A Cost-Effectiveness Analysis of Using the JBR. 10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non\u2013Small-Cell Lung Cancer"], ["D Galetta", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["K Syrigos", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["H Asamura", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["Hans Hoffmann", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["W Weder", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["M Yoshimura", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["R Rintoul", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["U Pastorino", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["A Bille", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["J van Meerbeeck", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["J Friedberg", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["H Batirel", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["A Nowak", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["A Cangir", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["J Vansteenkiste", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["F Rea", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["C Atinkaya Ozturk", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["T Nakano", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["I Opitz", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["Jan P Van Meerbeeck", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["S Call", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["Ayten K Cangir", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["D Rice", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["K Kernstine", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["S Cedres", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["H Kindler", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["David Waller", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["M de Perrot", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["F Galateau-Salle", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["L Spaggiari", 2016, "The IASLC mesothelioma staging project: improving staging of a rare disease through international participation"], ["David C Rice", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Joseph Friedberg", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["P Nafteux", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Susana Cedres", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["S Hasagawa", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["I Optiz", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Charles F Thomas", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Andrea Bill\u00e9", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Robert C Rintoul", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Hasan F Batirel", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Toni Lerut", 2016, "The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM \u2026"], ["JP van Meerbeeck", 2016, "The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM \u2026"], ["Masahiro Yoshimura", 2016, "The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM \u2026"], ["Brian C McCaughan", 2016, "The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM \u2026"], ["F Galateau-Sall\u00e9", 2016, "The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM \u2026"], ["Lorenzo Spaggiari", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Federico Rea", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Joseph S Friedberg", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Robert Rintoul", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Hasan Batirel", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["KN Syrigos", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Charles Thomas", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Kemp H Kernstine", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Brian McCaughan", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Domenico Galetta", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Sergi Call", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Philippe Nafteux", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Seiki Hasagawa", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Cansel Atinkaya", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Cansel Atinkaya Ozturk", 2016, "The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma"], ["Mateya Trinkaus", 2016, "Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial"], ["Hal K Berman", 2016, "Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial"], ["Trevor J Pugh", 2016, "Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial"], ["Raymond H Kim", 2016, "Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial"], ["Patricia Shaw", 2016, "Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial"], ["Neesha Dhani", 2016, "Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial"], ["Mahadeo A Sukhai", 2016, "Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial"], ["Anthony M Joshua", 2016, "Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial"], ["Nadia Califaretti", 2016, "Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial"], ["Carl Virtanen", 2016, "Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial"], ["Tracy L Stockley", 2016, "Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial"], ["Marileila Varella-Garcia", 2016, "An Anaplastic Lymphoma Kinase Immunohistochemistry\u2013Negative but Fluorescence In Situ Hybridization\u2013Positive Lung Adenocarcinoma Is Resistant to Crizotinib"], ["Arnavaz Danesh", 2016, "An Anaplastic Lymphoma Kinase Immunohistochemistry\u2013Negative but Fluorescence In Situ Hybridization\u2013Positive Lung Adenocarcinoma Is Resistant to Crizotinib"], ["Takaya Suzuki", 2016, "SOX2 and PI3K cooperate to induce and stabilize a squamous-committed stem cell injury state during lung squamous cell carcinoma pathogenesis"], ["Thomas K Waddell", 2016, "SOX2 and PI3K cooperate to induce and stabilize a squamous-committed stem cell injury state during lung squamous cell carcinoma pathogenesis"], ["Bizhan Bandarchi", 2016, "SOX2 and PI3K cooperate to induce and stabilize a squamous-committed stem cell injury state during lung squamous cell carcinoma pathogenesis"], ["Shintaro Tarumi", 2016, "SOX2 and PI3K cooperate to induce and stabilize a squamous-committed stem cell injury state during lung squamous cell carcinoma pathogenesis"], ["Stefan Hasenoeder", 2016, "SOX2 and PI3K cooperate to induce and stabilize a squamous-committed stem cell injury state during lung squamous cell carcinoma pathogenesis"], ["Nhu An Pham", 2016, "SOX2 and PI3K cooperate to induce and stabilize a squamous-committed stem cell injury state during lung squamous cell carcinoma pathogenesis"], ["Eric Thunnissen", 2016, "Transbronchial lung cryobiopsy for interstitial lung disease diagnosis: A perspective from members of the pulmonary pathology society"], ["Vera Capelozzi", 2016, "Transbronchial lung cryobiopsy for interstitial lung disease diagnosis: A perspective from members of the pulmonary pathology society"], ["Annette M McWilliams", 2016, "Low prevalence of high-grade lesions detected with autofluorescence bronchoscopy in the setting of lung cancer screening in the pan-canadian lung cancer screening study"], ["Niloofar Taghizadeh", 2016, "Low prevalence of high-grade lesions detected with autofluorescence bronchoscopy in the setting of lung cancer screening in the pan-canadian lung cancer screening study"], ["Pan-Canadian Early Lung Cancer Study Group", 2016, "Low prevalence of high-grade lesions detected with autofluorescence bronchoscopy in the setting of lung cancer screening in the pan-canadian lung cancer screening study"], ["Tom G Sutedja", 2016, "Low prevalence of high-grade lesions detected with autofluorescence bronchoscopy in the setting of lung cancer screening in the pan-canadian lung cancer screening study"], ["David R Stather", 2016, "Low prevalence of high-grade lesions detected with autofluorescence bronchoscopy in the setting of lung cancer screening in the pan-canadian lung cancer screening study"], ["Andrew MK Brown", 2016, "A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns"], ["John MS Bartlett", 2016, "A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns"], ["Lars GT Jorgensen", 2016, "A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns"], ["A Hansen", 2016, "Prognostic Factors From Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["W Xu", 2016, "Prognostic Factors From Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["M Hyrcza", 2016, "Prognostic Factors From Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["SH Huang", 2016, "Prognostic Factors From Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["SV Bratman", 2016, "Prognostic Factors From Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["I Weinreb", 2016, "Prognostic Factors From Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["FF Liu", 2016, "Prognostic Factors From Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["M Butler", 2016, "Prognostic Factors From Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["D Goldstein", 2016, "Prognostic Factors From Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["SL Lee", 2016, "Prognostic Factors From Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["Y Song", 2016, "Prognostic Factors From Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["Jan van Meeerbeeck", 2016, "The IASLC lung cancer staging project: methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in the forthcoming \u2026"], ["Marcin Zielinski", 2016, "The IASLC lung cancer staging project: methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in the forthcoming \u2026"], ["John Mayo", 2016, "Plasma pro-surfactant protein B and lung function decline in smokers (vol 45, pg 1037, 2015)"], ["Stuart Peacock", 2016, "Plasma pro-surfactant protein B and lung function decline in smokers (vol 45, pg 1037, 2015)"], ["Wan Tan", 2016, "Plasma pro-surfactant protein B and lung function decline in smokers (vol 45, pg 1037, 2015)"], ["C Martin Tammemagi", 2016, "Plasma pro-surfactant protein B and lung function decline in smokers (vol 45, pg 1037, 2015)"], ["John Goffin", 2016, "Plasma pro-surfactant protein B and lung function decline in smokers (vol 45, pg 1037, 2015)"], ["Janice M Leung", 2016, "Plasma pro-surfactant protein B and lung function decline in smokers (vol 45, pg 1037, 2015)"], ["Aaron Hansen", 2016, "29: Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["Scott Bratman", 2016, "29: Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["Yuyao Song", 2016, "29: Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["Marcus Butler", 2016, "29: Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["Sangjune Lee", 2016, "29: Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["Martin Hyrcza", 2016, "29: Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["Shao Hui Huang", 2016, "29: Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["Fei-Fei Liu", 2016, "29: Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["Ilan Weinreb", 2016, "29: Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["David Goldstein", 2016, "29: Computer-Assisted Image Analysis of an Oral Cavity Squamous Cell Carcinoma Tissue Microarray"], ["Thomas Friess", 2016, "Cetuximab inhibits T790M-mediated resistance to epidermal growth factor receptor tyrosine kinase inhibitor in a lung adenocarcinoma patient-derived xenograft mouse model"], ["Jenna Sykes", 2016, "Cetuximab inhibits T790M-mediated resistance to epidermal growth factor receptor tyrosine kinase inhibitor in a lung adenocarcinoma patient-derived xenograft mouse model"], ["Devang Panchal", 2016, "Cetuximab inhibits T790M-mediated resistance to epidermal growth factor receptor tyrosine kinase inhibitor in a lung adenocarcinoma patient-derived xenograft mouse model"], ["Rob Denroch", 2016, "Abstract B31: Establishment and molecular characterization of patient-derived tumor xenografts from resected tumors or ascites fluids of patients with pancreatic/ampullary/bile \u2026"], ["Steve Gallinger", 2016, "Abstract B31: Establishment and molecular characterization of patient-derived tumor xenografts from resected tumors or ascites fluids of patients with pancreatic/ampullary/bile \u2026"], ["Lincoln Stein", 2016, "Abstract B31: Establishment and molecular characterization of patient-derived tumor xenografts from resected tumors or ascites fluids of patients with pancreatic/ampullary/bile \u2026"], ["Tracy Zhao", 2016, "Abstract B31: Establishment and molecular characterization of patient-derived tumor xenografts from resected tumors or ascites fluids of patients with pancreatic/ampullary/bile \u2026"], ["John McPherson", 2016, "Abstract B31: Establishment and molecular characterization of patient-derived tumor xenografts from resected tumors or ascites fluids of patients with pancreatic/ampullary/bile \u2026"], ["Carson Holt", 2016, "Abstract B31: Establishment and molecular characterization of patient-derived tumor xenografts from resected tumors or ascites fluids of patients with pancreatic/ampullary/bile \u2026"], ["Alexander A Bankier", 2016, "The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth \u2026"], ["Mathias Prokop", 2016, "The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth \u2026"], ["David Naidich", 2016, "The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth \u2026"], ["Jan Van Meerbeeck", 2016, "The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth \u2026"], ["Charles A Powell", 2016, "The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth \u2026"], ["S Shapera", 2016, "Anti-PD-1-associated organizing pneumonia in a responding melanoma patient"], ["PO Fiset", 2016, "Anti-PD-1-associated organizing pneumonia in a responding melanoma patient"], ["MO Butler", 2016, "Anti-PD-1-associated organizing pneumonia in a responding melanoma patient"], ["David Yankelevitz", 2016, "The international association for the study of lung cancer consensus statement on optimizing management of EGFR Mutation\u2013Positive Non\u2013Small cell lung cancer: status in 2016"], ["David P Carbone", 2016, "The international association for the study of lung cancer consensus statement on optimizing management of EGFR Mutation\u2013Positive Non\u2013Small cell lung cancer: status in 2016"], ["Rex C Yung", 2016, "The international association for the study of lung cancer consensus statement on optimizing management of EGFR Mutation\u2013Positive Non\u2013Small cell lung cancer: status in 2016"], ["Philip C Mack", 2016, "The international association for the study of lung cancer consensus statement on optimizing management of EGFR Mutation\u2013Positive Non\u2013Small cell lung cancer: status in 2016"], ["Paul A Bunn Jr", 2016, "The international association for the study of lung cancer consensus statement on optimizing management of EGFR Mutation\u2013Positive Non\u2013Small cell lung cancer: status in 2016"], ["Daniel SW Tan", 2016, "The international association for the study of lung cancer consensus statement on optimizing management of EGFR Mutation\u2013Positive Non\u2013Small cell lung cancer: status in 2016"], ["Karen Kelly", 2016, "The international association for the study of lung cancer consensus statement on optimizing management of EGFR Mutation\u2013Positive Non\u2013Small cell lung cancer: status in 2016"], ["Tony SK Mok", 2016, "The international association for the study of lung cancer consensus statement on optimizing management of EGFR Mutation\u2013Positive Non\u2013Small cell lung cancer: status in 2016"], ["Sue S Yom", 2016, "The international association for the study of lung cancer consensus statement on optimizing management of EGFR Mutation\u2013Positive Non\u2013Small cell lung cancer: status in 2016"], ["Michael Unger", 2016, "The international association for the study of lung cancer consensus statement on optimizing management of EGFR Mutation\u2013Positive Non\u2013Small cell lung cancer: status in 2016"], ["Roy S Herbst", 2016, "The international association for the study of lung cancer consensus statement on optimizing management of EGFR Mutation\u2013Positive Non\u2013Small cell lung cancer: status in 2016"], ["Mauro Ajaj Saieg", 2016, "A proposal for cellularity assessment for EGFR mutational analysis with a correlation with DNA yield and evaluation of the number of sections obtained from cell blocks for \u2026"], ["Allie Reid", 2016, "A proposal for cellularity assessment for EGFR mutational analysis with a correlation with DNA yield and evaluation of the number of sections obtained from cell blocks for \u2026"], ["Tyler Wyeth", 2016, "A proposal for cellularity assessment for EGFR mutational analysis with a correlation with DNA yield and evaluation of the number of sections obtained from cell blocks for \u2026"], ["Pinjiang Cao", 2016, "Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302"], ["Joanna Rasowski", 2016, "Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302"], ["Trevor Do", 2016, "Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302"], ["Richard P Hill", 2016, "Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302"], ["Ines Lohse", 2016, "Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302"], ["Shiyun Ling", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Daniel J Crain", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Andrew D Cherniack", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Catherine J Wu", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Peter W Laird", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Lynda Chin", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Joel S Parker", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Leslie Cope", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Gordon B Mills", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Charlie Sun", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Corbin D Jones", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Tom Bodenheimer", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["J Todd Auman", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Lauren A Byers", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Peter Park", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Mark Sherman", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Jeffrey Roach", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Hendrik Dienemann", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Matthew Meyerson", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Junyuan Wu", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Gordon Saksena", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Hailei Zhang", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Kevin Lau", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Guangwu Guo", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Mark Gerken", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Chad J Creighton", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Tara M Lichtenberg", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Rehan Akbani", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["David I Heiman", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Michael S Noble", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Lori Boice", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Joeseph Paulauskis", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Johanna Gardner", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["James G Herman", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Jiashan Zhang", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Rameen Beroukhim", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Rashi Naresh", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Saianand Balu", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Scott Frazer", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Erin Curley", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Martin Peifer", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["John A Demchok", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Aruna Ramachandran", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Martin L Ferguson", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Bradley A Murray", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Alice H Berger", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Raju Kucherlapati", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Liming Yang", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Phillip H Lai", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Roy Tarnuzzer", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Jia Liu", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Jay Bowen", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Katherine A Hoadley", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Janae V Simons", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Heidi J Sofia", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Carolyn M Hutter", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Lisle E Mose", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Yunhu Wan", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Mara Rosenberg", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Todd Pihl", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Sudha Chudamani", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["David Kwiatkowski", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Marcin Imielinski", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Robert Schreiber", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Peter S Hammerman", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Juok Cho", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Alan P Hoyle", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Stephen B Baylin", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Roel GW Verhaak", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Stacey B Gabriel", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Peggy Yena", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["W Kimryn Rathmell", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Lisa Wise", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Mei Huang", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Carrie Sougnez", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Zhining Wang", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Ina Felau", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Tara Skelly", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Ye Wu", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Travis I Zack", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Anton Alexandrov", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["D Neil Hayes", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Jaegil Kim", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Piotr A Mieczkowski", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Julie M Gastier-Foster", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Kristen M Leraas", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Candace Shelton", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Juliann Shih", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Leigh B Thorne", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Yan Shi", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Nils Gehlenborg", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Pei Lin", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Chandra Sekhar Pedamallu", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Charles M Perou", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Doug Voet", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Michael Meister", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Daniel J Weisenberger", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["David Mallery", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Steven E Schumacher", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Xin Hu", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Erik Zmuda", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Cancer Genome Atlas Research Network", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Matthew G Soloway", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Carrie Cibulskis", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Joshua D Campbell", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Scott Morris", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Eric A Collisson", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Tanja Davidsen", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["John N Weinstein", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Laxmi Lolla", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Jeremiah Wala", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Eric Collisson", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Sachet A Shukla", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Troy Shelton", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Angela N Brooks", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Maxim N Artyomov", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Umadevi Veluvolu", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Josh Stuart", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Ludmila Danilova", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Nilsa C Ramirez", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Matthew D Wilkerson", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Michael S Lawrence", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Shaowu Meng", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Gad Getz", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["David J Van Den Berg", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Dennis T Maglinte", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Stuart R Jefferys", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Donghui Tan", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Moiz S Bootwalla", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Jean C Zenklusen", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Robert Penny", 2016, "Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"], ["Brian E Cade", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Eliza Van Reen", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Miriam Munch", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Jeanne F Duffy", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Susan Redline", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Diane S Lauderdale", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Nayantara Santhi", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Sanjay Patel", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Sina A Gharib", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Melanie Rueger", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Andrew C Bjonnes", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Steven W Lockley", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Struan FA Grant", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Frank AJL Scheer", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Elizabeth B Klerman", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Orfeu M Buxton", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Sean W Cain", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Shanthakumar MW Rajaratnam", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Phyllis C Zee", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Karin Scheuermaier", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Clare Anderson", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Steven A Shea", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Charles A Czeisler", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Naresh M Punjabi", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Daniel J Gottlieb", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Anne-Marie Chang", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Daniel Aeschbach", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Joshua J Gooley", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Melissa A St Hilaire", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Jacqueline M Lane", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["Richa Saxena", 2016, "Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology"], ["DG Bebb", 2016, "Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer"], ["SA Laurie", 2016, "Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer"], ["J Agulnik", 2016, "Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer"], ["J Deschenes", 2016, "Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer"], ["S Banerji", 2016, "Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer"], ["W Morzycki", 2016, "Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer"], ["P Cheung", 2016, "Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer"], ["V Cohen", 2016, "Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer"], ["R Albadine", 2016, "Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer"], ["D Bethune", 2016, "Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer"], ["LACE-Bio Collaborative Group", 2016, "Prognostic and Predictive Effect of TP53 Mutations in Patients with Non\u2013Small Cell Lung Cancer from Adjuvant Cisplatin\u2013Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis"], ["Xiaoli Ma", 2016, "Prognostic and Predictive Effect of TP53 Mutations in Patients with Non\u2013Small Cell Lung Cancer from Adjuvant Cisplatin\u2013Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis"], ["Chandra Goparaju", 2016, "Plasma biomarker enrichment of clinical prognostic indices in malignant pleural mesothelioma"], ["Shirish Gadgeel", 2016, "Plasma biomarker enrichment of clinical prognostic indices in malignant pleural mesothelioma"], ["John Cho", 2016, "Plasma biomarker enrichment of clinical prognostic indices in malignant pleural mesothelioma"], ["Abraham Chachoua", 2016, "Plasma biomarker enrichment of clinical prognostic indices in malignant pleural mesothelioma"], ["Osvaldo Espin-Garcia", 2016, "Plasma biomarker enrichment of clinical prognostic indices in malignant pleural mesothelioma"], ["Jessica Donington", 2016, "Plasma biomarker enrichment of clinical prognostic indices in malignant pleural mesothelioma"], ["Antoinette Wozniak", 2016, "Plasma biomarker enrichment of clinical prognostic indices in malignant pleural mesothelioma"], ["Michele Carbone", 2016, "Plasma biomarker enrichment of clinical prognostic indices in malignant pleural mesothelioma"], ["Catherine Labbe", 2016, "Prognostic and predictive effects of TP53 mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)."], ["Adrian G Sacher", 2016, "A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer"], ["Lisa W Le", 2016, "A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer"], ["Humberto Lara-Guerra", 2016, "A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer"], ["Alexandra Salvarrey", 2016, "A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer"], ["Charles Powell", 2016, "The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming \u2026"], ["Myrna Godoy", 2016, "The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming \u2026"], ["Jessica S Donington", 2016, "The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming \u2026"], ["Paul de Leyn", 2016, "The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming \u2026"], ["Peter J Mazzone", 2016, "The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming \u2026"], ["J Hern\u00e1ndez", 2016, "The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming \u2026"], ["Lawrence R Goodman", 2016, "The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming \u2026"], ["Morohito Okada", 2016, "The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming \u2026"], ["Lynn T Tanoue", 2016, "The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming \u2026"], ["Jim Jett", 2016, "The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming \u2026"], ["Douglas A Arenberg", 2016, "The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming \u2026"], ["Marina Perlman", 2016, "The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming \u2026"], ["Ghasson Allo", 2016, "Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 \u2026"], ["Sasha Lupichuk", 2016, "Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 \u2026"], ["Maria Bonomi", 2016, "Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 \u2026"], ["Tamara Shenkier", 2016, "Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 \u2026"], ["Muhammad Salim", 2016, "Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 \u2026"], ["Patricia Farmer", 2016, "Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 \u2026"], ["Alison Allan", 2016, "Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 \u2026"], ["Catherine Prady", 2016, "Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 \u2026"], ["Sukhbinder Dhesy-Thind", 2016, "Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 \u2026"], ["Kylea Potvin", 2016, "Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 \u2026"], ["Daniel Rayson", 2016, "Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 \u2026"], ["Susan Dent", 2016, "Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 \u2026"], ["Julie R Brahmer", 2016, "Scientific advances in lung cancer 2015"], ["Yang Zhou", 2016, "Scientific advances in lung cancer 2015"], ["Heather A Wakelee", 2016, "Scientific advances in lung cancer 2015"], ["Thanyanan Reungwetwattana", 2016, "Scientific advances in lung cancer 2015"], ["Anne S Tsao", 2016, "Scientific advances in lung cancer 2015"], ["Kenneth E Rosenzweig", 2016, "Scientific advances in lung cancer 2015"], ["Sai-Hong Ignatius Ou", 2016, "Scientific advances in lung cancer 2015"], ["A Uraujh Yousaf-Khan", 2016, "Scientific advances in lung cancer 2015"], ["Gail E Darling", 2016, "Scientific advances in lung cancer 2015"], ["Vassiliki A Papadimitrakopoulou", 2016, "Scientific advances in lung cancer 2015"], ["Daniel R Gomez", 2016, "Scientific advances in lung cancer 2015"], ["Stefan Zimmermann", 2016, "Scientific advances in lung cancer 2015"], ["Graham W Warren", 2016, "Scientific advances in lung cancer 2015"], ["Chunxue Bai", 2016, "Scientific advances in lung cancer 2015"], ["Paul E Van Schil", 2016, "Scientific advances in lung cancer 2015"], ["Tony S Mok", 2016, "Scientific advances in lung cancer 2015"], ["Mary W Redman", 2016, "Scientific advances in lung cancer 2015"], ["Suresh S Ramalingam", 2016, "Scientific advances in lung cancer 2015"], ["Prasad S Adusumilli", 2016, "Scientific advances in lung cancer 2015"], ["Ronan J Kelly", 2016, "Scientific advances in lung cancer 2015"], ["Solange Peters", 2016, "Scientific advances in lung cancer 2015"], ["Giorgio V Scagliotti", 2016, "Scientific advances in lung cancer 2015"], ["Harry J De Koning", 2016, "Scientific advances in lung cancer 2015"], ["Colin Jacobs", 2016, "Computer vision tool and technician as first reader of lung cancer screening CT scans"], ["Bram van Ginneken", 2016, "Computer vision tool and technician as first reader of lung cancer screening CT scans"], ["Cancer Study Group", 2016, "Computer vision tool and technician as first reader of lung cancer screening CT scans"], ["Calvin Sanghera", 2016, "Computer vision tool and technician as first reader of lung cancer screening CT scans"], ["Wei Zhang", 2016, "Computer vision tool and technician as first reader of lung cancer screening CT scans"], ["Pan-Canadian Early Detection of Lung", 2016, "Computer vision tool and technician as first reader of lung cancer screening CT scans"], ["Alexander J Ritchie", 2016, "Computer vision tool and technician as first reader of lung cancer screening CT scans"], ["Sophie Marguet", 2016, "Prognostic effect of tumor lymphocytic infiltration in resectable non\u2013small-cell lung cancer"], ["Rafael Rosell", 2016, "Prognostic effect of tumor lymphocytic infiltration in resectable non\u2013small-cell lung cancer"], ["Ariane Dunant", 2016, "Prognostic effect of tumor lymphocytic infiltration in resectable non\u2013small-cell lung cancer"], ["Helmut Popper", 2016, "Prognostic effect of tumor lymphocytic infiltration in resectable non\u2013small-cell lung cancer"], ["Sharon Marsh", 2016, "ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR. 24 trial of platinum-treated advanced stage non-small cell lung \u2026"], ["Xiaoping Qiu", 2016, "ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR. 24 trial of platinum-treated advanced stage non-small cell lung \u2026"], ["Qin Kuang", 2016, "ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR. 24 trial of platinum-treated advanced stage non-small cell lung \u2026"], ["Sevtap Savas", 2016, "ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR. 24 trial of platinum-treated advanced stage non-small cell lung \u2026"], ["members of the Pulmonary Pathology Society", 2016, "Programmed death ligand-1 immunohistochemistry\u2014a new challenge for pathologists: a perspective from members of the Pulmonary Pathology Society"], ["Lida Hariri", 2016, "Programmed death ligand-1 immunohistochemistry\u2014a new challenge for pathologists: a perspective from members of the Pulmonary Pathology Society"], ["M Barczyk", 2016, "Integrin \u03b111\u03b21 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer"], ["CJ Park", 2016, "Integrin \u03b111\u03b21 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer"], ["D Strumpf", 2016, "Integrin \u03b111\u03b21 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer"], ["J Hai", 2016, "Integrin \u03b111\u03b21 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer"], ["C To", 2016, "Integrin \u03b111\u03b21 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer"], ["NA Pham", 2016, "Integrin \u03b111\u03b21 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer"], ["J Jonkman", 2016, "Integrin \u03b111\u03b21 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer"], ["B Bandarchi", 2016, "Integrin \u03b111\u03b21 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer"], ["J Liu", 2016, "Integrin \u03b111\u03b21 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer"], ["E Ibrahimov", 2016, "Integrin \u03b111\u03b21 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer"], ["GC Walker", 2016, "Integrin \u03b111\u03b21 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer"], ["CQ Zhu", 2016, "Integrin \u03b111\u03b21 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer"], ["K Venkat", 2016, "Integrin \u03b111\u03b21 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer"], ["KS Kim", 2016, "Integrin \u03b111\u03b21 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer"], ["YH Wang", 2016, "Integrin \u03b111\u03b21 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer"], ["A Lu", 2016, "Integrin \u03b111\u03b21 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer"], ["D Gullberg", 2016, "Integrin \u03b111\u03b21 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer"], ["Wilfried EE Eberhardt", 2016, "The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung \u2026"], ["Jing Li", 2016, "Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients"], ["Brian Higgins", 2016, "Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients"], ["Matilda Ng", 2016, "Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients"], ["Roxana Tudor", 2016, "Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients"], ["Carolyn J Shiau", 2016, "Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients"], ["Sara Kuruvilla", 2016, "Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients"], ["Maria Pasic", 2016, "Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients"], ["Anthea Lau", 2016, "Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients"], ["Stephanie Lin", 2016, "Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients"], ["Susanna Cheng", 2016, "Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients"], ["Stacy Hubay", 2016, "Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients"], ["Saroosh Arif", 2016, "Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients"], ["Peter M Ellis", 2016, "Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients"], ["Nicole Beauchemin", 2016, "From Solo in the Silo to Strategic Training Programs"], ["Barbara Riley", 2016, "From Solo in the Silo to Strategic Training Programs"], ["Carmen G Loiselle", 2016, "From Solo in the Silo to Strategic Training Programs"], ["James Koropatnick", 2016, "From Solo in the Silo to Strategic Training Programs"], ["Wilson H Miller Jr", 2016, "From Solo in the Silo to Strategic Training Programs"], ["Gerry Johnston", 2016, "From Solo in the Silo to Strategic Training Programs"], ["C Anne Koch", 2016, "From Solo in the Silo to Strategic Training Programs"], ["Craig McCormick", 2016, "From Solo in the Silo to Strategic Training Programs"], ["Lois Mulligan", 2016, "From Solo in the Silo to Strategic Training Programs"], ["Magdalena Maslowska", 2016, "From Solo in the Silo to Strategic Training Programs"], ["Siow Ming Lee", 2016, "Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non\u2013Small Cell Lung Cancer Treated with Epidermal Growth \u2026"], ["Christopher J O\u2019Callaghan", 2016, "Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non\u2013Small Cell Lung Cancer Treated with Epidermal Growth \u2026"], ["Lei Han", 2016, "Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non\u2013Small Cell Lung Cancer Treated with Epidermal Growth \u2026"], ["Allan Hackshaw", 2016, "Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non\u2013Small Cell Lung Cancer Treated with Epidermal Growth \u2026"], ["Pierre Fiset", 2016, "ALK Rearragnement Testing by Immunohistochemistry and Fluorescent In Situ Hybridization in Lung Cancers: A Canadian Reference Testing Center's Routine Clinical Experience"], ["Masaaki Sato", 2016, "Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients"], ["Hideki Ujiie", 2016, "Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients"], ["Kentaro Hirohashi", 2016, "Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients"], ["Tatsuya Kato", 2016, "Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients"], ["Priya Patel", 2016, "Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients"], ["Takahiro Nakajima", 2016, "Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients"], ["Kichizo Kaga", 2016, "Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients"], ["Yoshiro Matsui", 2016, "Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients"], ["Hsin-pei Hu", 2016, "Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients"], ["Daiyoon Lee", 2016, "Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients"], ["Mitsuhito Kaji", 2016, "Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients"], ["Hironobu Wada", 2016, "Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients"], ["S Yi Eunhee", 2016, "Diagnosis of Acute Cellular Rejection and Antibody-Mediated Rejection on Lung Transplant Biopsies"], ["Timothy C Allen", 2016, "Diagnosis of Acute Cellular Rejection and Antibody-Mediated Rejection on Lung Transplant Biopsies"], ["A Frances", 2016, "Low Prevalence of High Grade Lesions Detected with Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study"], ["MDCM Alain Tremblay", 2016, "Low Prevalence of High Grade Lesions Detected with Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study"], ["MD Shepherd", 2016, "Low Prevalence of High Grade Lesions Detected with Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study"], ["Tony Sourisseau", 2016, "MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer"], ["Vladimir Lazar", 2016, "MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer"], ["Chang Q Zhu", 2016, "MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer"], ["Alexandre Civet", 2016, "MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer"], ["Angelique Robin", 2016, "MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer"], ["Ken A Olaussen", 2016, "MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer"], ["Philippe Girard", 2016, "MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer"], ["Alexandre Templier", 2016, "MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer"], ["Benjamin Besse", 2016, "MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer"], ["Pierre Validire", 2016, "MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer"], ["Kyaw L Aung", 2016, "Pan-cancer analysis of hotspot mutations in genes encoding the members of mitogen activated protein kinase (MAPK) and phosphoinosidtide-3 kinase (PI3K) pathways among smokers \u2026"], ["Greg Korpanty", 2016, "Pan-cancer analysis of hotspot mutations in genes encoding the members of mitogen activated protein kinase (MAPK) and phosphoinosidtide-3 kinase (PI3K) pathways among smokers \u2026"], ["Michael Roehrl", 2016, "Abstract PR03: Molecular profiling of advanced solid tumors at Princess Margaret Cancer Centre and patient outcomes with genotype-matched clinical trials"], ["Anca Milea", 2016, "Abstract PR03: Molecular profiling of advanced solid tumors at Princess Margaret Cancer Centre and patient outcomes with genotype-matched clinical trials"], ["Albiruni Razak", 2016, "Abstract PR03: Molecular profiling of advanced solid tumors at Princess Margaret Cancer Centre and patient outcomes with genotype-matched clinical trials"], ["Amit Oza", 2016, "Abstract PR03: Molecular profiling of advanced solid tumors at Princess Margaret Cancer Centre and patient outcomes with genotype-matched clinical trials"], ["Hirofumi Fujii", 2016, "Prognostic significance of hypoxic PET using 18F-FAZA and 62Cu-ATSM in non-small-cell lung cancer"], ["Tomonari Kinoshita", 2016, "Prognostic significance of hypoxic PET using 18F-FAZA and 62Cu-ATSM in non-small-cell lung cancer"], ["Yuichiro Hayashi", 2016, "Prognostic significance of hypoxic PET using 18F-FAZA and 62Cu-ATSM in non-small-cell lung cancer"], ["Takashi Ohtsuka", 2016, "Prognostic significance of hypoxic PET using 18F-FAZA and 62Cu-ATSM in non-small-cell lung cancer"], ["Ikuo Kamiyama", 2016, "Prognostic significance of hypoxic PET using 18F-FAZA and 62Cu-ATSM in non-small-cell lung cancer"], ["Robert A Grant", 2015, "A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy"], ["Karl A Merrick", 2015, "A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy"], ["Michael B Yaffe", 2015, "A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy"], ["Eleanor R Cameron", 2015, "A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy"], ["Sandra Morandell", 2015, "A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy"], ["Ian G Cannell", 2015, "A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy"], ["Michael T Hemann", 2015, "A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy"], ["Christian J Braun", 2015, "A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy"], ["Valentin Goede", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Michael Kneba", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Martina Stauch", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Hartmut D\u00f6hner", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Thomas Elter", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Clemens-Martin Wendtner", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Petra Langerbeins", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Michael Hallek", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Kirsten Fischer", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Elisabeth Lange", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Gabor Kovacs", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Natali Pflug", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Barbara Eichhorst", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Paula Cramer", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Manuela Bergmann", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Stephan Stilgenbauer", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Susanne Isfort", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Jasmin Bahlo", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Anna-Maria Fink", 2015, "Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group \u2026"], ["Yukito Ichinose", 2015, "Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy"], ["Tomoyoshi Takenaka", 2015, "Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy"], ["Andrea Bezjak", 2015, "Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy"], ["Yosuke Morodomi", 2015, "Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy"], ["Yoshihiko Maehara", 2015, "Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy"], ["Tatsuro Okamoto", 2015, "Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy"], ["Mitsuhiro Takenoyama", 2015, "Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy"], ["Audrey Holtzinger", 2015, "Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell\u2013and patient-derived tumor organoids"], ["Ling Huang", 2015, "Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell\u2013and patient-derived tumor organoids"], ["Gordon Keller", 2015, "Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell\u2013and patient-derived tumor organoids"], ["Michael BeGora", 2015, "Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell\u2013and patient-derived tumor organoids"], ["Steve E Kalloger", 2015, "Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell\u2013and patient-derived tumor organoids"], ["Nicholas Ngai", 2015, "Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell\u2013and patient-derived tumor organoids"], ["Ishaan Jagan", 2015, "Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell\u2013and patient-derived tumor organoids"], ["Daniel J Renouf", 2015, "Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell\u2013and patient-derived tumor organoids"], ["Cheryl Arrowsmith", 2015, "Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell\u2013and patient-derived tumor organoids"], ["Senthil K Muthuswamy", 2015, "Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell\u2013and patient-derived tumor organoids"], ["Cristina Nostro", 2015, "Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell\u2013and patient-derived tumor organoids"], ["Rennian Wang", 2015, "Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell\u2013and patient-derived tumor organoids"], ["Sean Cleary", 2015, "Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell\u2013and patient-derived tumor organoids"], ["David F Schaeffer", 2015, "Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell\u2013and patient-derived tumor organoids"], ["Howard C Crawford", 2015, "Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell\u2013and patient-derived tumor organoids"], ["Lakshmi B Muthuswamy", 2015, "Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell\u2013and patient-derived tumor organoids"], ["Helmut H Popper", 2015, "Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection"], ["Elisabeth M Brambilla", 2015, "Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection"], ["David Stather", 2015, "Low Prevalence of High Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study"], ["Harmanjatinder Sekhon", 2015, "Low Prevalence of High Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study"], ["Bram Van Ginneken", 2015, "Automated Measurement of Malignancy Risk of Lung Nodule Detected by Screening Computed Tomography"], ["Martin Tammemaegi", 2015, "Automated Measurement of Malignancy Risk of Lung Nodule Detected by Screening Computed Tomography"], ["Kenneth Olaussen", 2015, "Genome-Wide Gene Copy Number Analysis by OncoScan (TM) FFPE Assay in 976 Resected NSCLC From LACE-Bio2"], ["Gilbert C Walker", 2015, "Integrin a11b1 Regulates Cancer Stromal Stiffness and Promotes Tumorigenicity and Metastasis in Non-Small Cell Lung Cancer"], ["Kris S Kim", 2015, "Integrin a11b1 Regulates Cancer Stromal Stiffness and Promotes Tumorigenicity and Metastasis in Non-Small Cell Lung Cancer"], ["Ludovic Dhont", 2015, "Second Generation EGFR TKIs Inhibit Tumor Growth in a Chemo-Resistant Squamous Cell Lung Cancer Patient Derived Xenograft Model"], ["Spencer Hu", 2015, "Overexpression of KIF23 Predicts Clinical Outcome in Primary Lung Cancer Patients"], ["Melania Pintilier", 2015, "Functional Role of Cancer Associated Fibroblasts in Non-Small Cell Lung Cancer Patients"], ["Jing Hao", 2015, "Functional Role of Cancer Associated Fibroblasts in Non-Small Cell Lung Cancer Patients"], ["Philipp Alberts", 2015, "Patient-Derived Xenograft Studies Suggest FGFR1 Amplification Is Insufficient to Predict Response to FGFR Inhibitors in Lung SqCC"], ["John HM Austin", 2015, "The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification"], ["Shantanu Banerji", 2015, "Phase II study of PX-866 in recurrent glioblastoma"], ["Jacob C Easaw", 2015, "Phase II study of PX-866 in recurrent glioblastoma"], ["David R Macdonald", 2015, "Phase II study of PX-866 in recurrent glioblastoma"], ["Brian Thiessen", 2015, "Phase II study of PX-866 in recurrent glioblastoma"], ["Warren P Mason", 2015, "Phase II study of PX-866 in recurrent glioblastoma"], ["Mary V MacNeil", 2015, "Phase II study of PX-866 in recurrent glioblastoma"], ["Jeremy Squire", 2015, "Phase II study of PX-866 in recurrent glioblastoma"], ["Ankineedu S Kakumanu", 2015, "Phase II study of PX-866 in recurrent glioblastoma"], ["David D Eisenstat", 2015, "Phase II study of PX-866 in recurrent glioblastoma"], ["Diana F Hausman", 2015, "Phase II study of PX-866 in recurrent glioblastoma"], ["Marshall W Pitz", 2015, "Phase II study of PX-866 in recurrent glioblastoma"], ["Elizabeth A Eisenhauer", 2015, "Phase II study of PX-866 in recurrent glioblastoma"], ["Tom John", 2015, "Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma"], ["Yu-hui Wang", 2015, "Patient-derived tumor xenograft models established from samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration"], ["William Geddie", 2015, "Patient-derived tumor xenograft models established from samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration"], ["Takashi Anayama", 2015, "Patient-derived tumor xenograft models established from samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration"], ["Hyang Mi Ko", 2015, "Patient-derived tumor xenograft models established from samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration"], ["William W Lockwood", 2015, "Coiled-coil domain containing 68 (CCDC68) demonstrates a tumor-suppressive role in pancreatic ductal adenocarcinoma"], ["Jason Moffat", 2015, "Coiled-coil domain containing 68 (CCDC68) demonstrates a tumor-suppressive role in pancreatic ductal adenocarcinoma"], ["Kelsie L Thu", 2015, "Coiled-coil domain containing 68 (CCDC68) demonstrates a tumor-suppressive role in pancreatic ductal adenocarcinoma"], ["Yaroslav Fedyshyn", 2015, "Coiled-coil domain containing 68 (CCDC68) demonstrates a tumor-suppressive role in pancreatic ductal adenocarcinoma"], ["Lisa Leung", 2015, "Coiled-coil domain containing 68 (CCDC68) demonstrates a tumor-suppressive role in pancreatic ductal adenocarcinoma"], ["Pinjian Cao", 2015, "Combination treatment with hypoxia-activated prodrug TH-302 and radiation reduce pancreatic tumor initiating cells and tumor growth in patient-derived xenografts"], ["A Borgida", 2015, "BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts"], ["RG Bristow", 2015, "BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts"], ["M Cheung", 2015, "BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts"], ["I Lohse", 2015, "BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts"], ["T Bianco", 2015, "BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts"], ["S Gallinger", 2015, "BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts"], ["R Kumareswaran", 2015, "BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts"], ["S Holter", 2015, "BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts"], ["P Cao", 2015, "BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts"], ["DW Hedley", 2015, "BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts"], ["Arlette H Uihlein", 2015, "Analytical performance of a 15-gene prognostic assay for early-stage non\u2013small-cell lung carcinoma using RNA-stabilized tissue"], ["Tianhua Wang", 2015, "Analytical performance of a 15-gene prognostic assay for early-stage non\u2013small-cell lung carcinoma using RNA-stabilized tissue"], ["Timothy Davison", 2015, "Analytical performance of a 15-gene prognostic assay for early-stage non\u2013small-cell lung carcinoma using RNA-stabilized tissue"], ["Stacey L Brower", 2015, "Analytical performance of a 15-gene prognostic assay for early-stage non\u2013small-cell lung carcinoma using RNA-stabilized tissue"], ["Katherine E Keating", 2015, "Analytical performance of a 15-gene prognostic assay for early-stage non\u2013small-cell lung carcinoma using RNA-stabilized tissue"], ["Shuguang Huang", 2015, "Analytical performance of a 15-gene prognostic assay for early-stage non\u2013small-cell lung carcinoma using RNA-stabilized tissue"], ["Claire Wilson", 2015, "Analytical performance of a 15-gene prognostic assay for early-stage non\u2013small-cell lung carcinoma using RNA-stabilized tissue"], ["Nicholas J Reitze", 2015, "Analytical performance of a 15-gene prognostic assay for early-stage non\u2013small-cell lung carcinoma using RNA-stabilized tissue"], ["Dakun Wang", 2015, "Analytical performance of a 15-gene prognostic assay for early-stage non\u2013small-cell lung carcinoma using RNA-stabilized tissue"], ["Stuart McKenzie", 2015, "Analytical performance of a 15-gene prognostic assay for early-stage non\u2013small-cell lung carcinoma using RNA-stabilized tissue"], ["Victoria Plamadeala", 2015, "Analytical performance of a 15-gene prognostic assay for early-stage non\u2013small-cell lung carcinoma using RNA-stabilized tissue"], ["Amy L Ewing", 2015, "Analytical performance of a 15-gene prognostic assay for early-stage non\u2013small-cell lung carcinoma using RNA-stabilized tissue"], ["Jude Mulligan", 2015, "Analytical performance of a 15-gene prognostic assay for early-stage non\u2013small-cell lung carcinoma using RNA-stabilized tissue"], ["Suzanne McCreary", 2015, "Analytical performance of a 15-gene prognostic assay for early-stage non\u2013small-cell lung carcinoma using RNA-stabilized tissue"], ["Michael J Gabrin", 2015, "Analytical performance of a 15-gene prognostic assay for early-stage non\u2013small-cell lung carcinoma using RNA-stabilized tissue"], ["J Tanguay", 2015, "Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer"], ["R Feld", 2015, "Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer"], ["RL Burkes", 2015, "Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer"], ["LW Le", 2015, "Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer"], ["Ravi N Vellanki", 2015, "CHCHD2 is coamplified with EGFR in NSCLC and regulates mitochondrial function and cell migration"], ["\u00c9tienne Coyaud", 2015, "CHCHD2 is coamplified with EGFR in NSCLC and regulates mitochondrial function and cell migration"], ["Jonathan R Krieger", 2015, "CHCHD2 is coamplified with EGFR in NSCLC and regulates mitochondrial function and cell migration"], ["IASLC Pathology Committee", 2015, "Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art?"], ["Virginijus Barzda", 2015, "Tumor tissue characterization using polarization-sensitive second harmonic generation microscopy"], ["Carolyn Niu", 2015, "Tumor tissue characterization using polarization-sensitive second harmonic generation microscopy"], ["Danielle Tokarz", 2015, "Tumor tissue characterization using polarization-sensitive second harmonic generation microscopy"], ["Richard Cisek", 2015, "Tumor tissue characterization using polarization-sensitive second harmonic generation microscopy"], ["Serguei Krouglov", 2015, "Tumor tissue characterization using polarization-sensitive second harmonic generation microscopy"], ["Brian C Wilson", 2015, "Tumor tissue characterization using polarization-sensitive second harmonic generation microscopy"], ["Sylvia L Asa", 2015, "Tumor tissue characterization using polarization-sensitive second harmonic generation microscopy"], ["Ahmad Golaraei", 2015, "Tumor tissue characterization using polarization-sensitive second harmonic generation microscopy"], ["Desmond She", 2015, "NRF2 pathway activation and adjuvant chemotherapy benefit in lung squamous cell carcinoma"], ["Marguerite Ennis", 2015, "Prognostic effect of single versus multiple somatic mutations in non-small cell lung cancer (NSCLC)."], ["Bethany Gill", 2015, "Personalized treatment outcomes in never smokers with advanced non-small cell lung cancer (NSCLC) in the Princess Margaret Cancer Centre."], ["Michael B Sawyer", 2015, "NCIC CTG IND. 206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers."], ["Torsten O Nielsen", 2015, "NCIC CTG IND. 206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers."], ["Susan Ellard", 2015, "NCIC CTG IND. 206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers."], ["Scott Andrew Laurie", 2015, "NCIC CTG IND. 206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers."], ["Diane M Provencher", 2015, "NCIC CTG IND. 206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers."], ["Winson Y Cheung", 2015, "NCIC CTG IND. 206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers."], ["Robyn Jane Macfarlane", 2015, "NCIC CTG IND. 206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers."], ["Janet Dancey", 2015, "NCIC CTG IND. 206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers."], ["Donna Ann Wall", 2015, "NCIC CTG IND. 206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers."], ["Joana Sederias", 2015, "NCIC CTG IND. 206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers."], ["Abha A Gupta", 2015, "NCIC CTG IND. 206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers."], ["Sylvia Asa", 2015, "Characterization of Collagen in Human Pancreas, Breast and Lung with Polarization Resolved Second Harmonic Generation Microscopy"], ["S Tam", 2015, "Prognostic Classification of Lung Adenocarcinoma by Integrated Mirna-Mrna Expression Profiles"], ["JD McPherson", 2015, "Prognostic Classification of Lung Adenocarcinoma by Integrated Mirna-Mrna Expression Profiles"], ["S Sakashita", 2015, "48P DEVELOPMENT OF RESISTANCE MODELS TO TYROSINE KINASE INHIBITORS (TKIS) IN PATIENT-DERIVED XENOGRAFT MODELS (PDXS) OF LUNG ADENOCARCINOMA WITH EPIDERMAL GROWTH FACTOR \u2026"], ["EL Stewart", 2015, "48P DEVELOPMENT OF RESISTANCE MODELS TO TYROSINE KINASE INHIBITORS (TKIS) IN PATIENT-DERIVED XENOGRAFT MODELS (PDXS) OF LUNG ADENOCARCINOMA WITH EPIDERMAL GROWTH FACTOR \u2026"], ["N-A Pham", 2015, "48P DEVELOPMENT OF RESISTANCE MODELS TO TYROSINE KINASE INHIBITORS (TKIS) IN PATIENT-DERIVED XENOGRAFT MODELS (PDXS) OF LUNG ADENOCARCINOMA WITH EPIDERMAL GROWTH FACTOR \u2026"], ["T Wang", 2015, "48P DEVELOPMENT OF RESISTANCE MODELS TO TYROSINE KINASE INHIBITORS (TKIS) IN PATIENT-DERIVED XENOGRAFT MODELS (PDXS) OF LUNG ADENOCARCINOMA WITH EPIDERMAL GROWTH FACTOR \u2026"], ["Nathalie C Moon", 2015, "Integrating RAS status into prognostic signatures for adenocarcinomas of the lung"], ["Francis Nguyen", 2015, "Integrating RAS status into prognostic signatures for adenocarcinomas of the lung"], ["Linda Z Penn", 2015, "Integrating RAS status into prognostic signatures for adenocarcinomas of the lung"], ["Arek Kasprzyk", 2015, "Integrating RAS status into prognostic signatures for adenocarcinomas of the lung"], ["Philippe Lambin", 2015, "Integrating RAS status into prognostic signatures for adenocarcinomas of the lung"], ["Syed Haider", 2015, "Integrating RAS status into prognostic signatures for adenocarcinomas of the lung"], ["Maintainer Levi Waldron", 2015, "Package \u2018pensim\u2019"], ["L Waldron", 2015, "Package \u2018pensim\u2019"], ["S Tsao", 2015, "Package \u2018pensim\u2019"], ["C Huttenhower", 2015, "Package \u2018pensim\u2019"], ["Samuel Zhixing Tan", 2015, "Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations\u2014a review"], ["Jennifer Won", 2015, "Developing ALK-1 Immunohistochemistry and In Situ Hybridization Proficiency Testing: Canadian Immunohistochemistry Quality Control (CIQC) Experience"], ["Farnoosh Tayyari", 2015, "Gene Mutation Frequencies and Associations in Adenocarcinoma of the Lung"], ["Y Ishikawa", 2015, "WHO panel"], ["E Duhig", 2015, "WHO panel"], ["DB Flieder", 2015, "WHO panel"], ["CA Powell", 2015, "WHO panel"], ["JH Austin", 2015, "WHO panel"], ["LR Chirieac", 2015, "WHO panel"], ["K Geisinger", 2015, "WHO panel"], ["KM Kerr", 2015, "WHO panel"], ["Skin Oncology Team", 2015, "Squamous cell carcinoma"], ["Robert G Bristow", 2015, "Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers"], ["Henry Thai", 2015, "Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers"], ["Andrew Fleet", 2015, "Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers"], ["Laurie E Ailles", 2015, "Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers"], ["Xiaowei Shen", 2015, "Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers"], ["Lawson Eng", 2015, "Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers"], ["Joerg Schwock", 2015, "Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers"], ["Hala Girgis", 2015, "Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers"], ["Lorin Dodbiba", 2015, "Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers"], ["Jennifer Teichman", 2015, "Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers"]]}